Oncogenic and teratogenic effects of Trp53 Y217C , an inflammation-prone mouse model of the human hotspot mutant TP53 Y220C

Oncogenic and teratogenic effects of Trp53Y217C, an inflammation-prone mouse model of the human hotspot mutant TP53Y220C | bioRxiv /* */ /* */ <!-- <!-- /*! * yepnope1.5.4 * (c) WTFPL, GPLv2 */ (function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split("="),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-M677548'); Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results Oncogenic and teratogenic effects of Trp53 Y217C , an inflammation-prone mouse model of the human hotspot mutant TP53 Y220C Sara Jaber , Eliana Eldawra , Jeanne Rakotopare , Iva Simeonova , View ORCID Profile Vincent Lejour , Marc Gabriel , Tatiana Cañeque , Vitalina Volochtchouk , Monika Licaj , Anne Fajac , Raphaël Rodriguez , View ORCID Profile Antonin Morillon , View ORCID Profile Boris Bardot , View ORCID Profile Franck Toledo doi: https://doi.org/10.1101/2024.09.26.615223 Sara Jaber 1 Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eliana Eldawra 1 Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jeanne Rakotopare 1 Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Iva Simeonova 2 Chromatin dynamics, Institut Curie, CNRS UMR3664, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Vincent Lejour 1 Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Vincent Lejour Marc Gabriel 3 Non Coding RNA, Epigenetic and Genome Fluidity, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tatiana Cañeque 4 Chemical Biology, Institut Curie, CNRS UMR3666, INSERM U1143, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Vitalina Volochtchouk 1 Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Monika Licaj 1 Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anne Fajac 1 Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Raphaël Rodriguez 4 Chemical Biology, Institut Curie, CNRS UMR3666, INSERM U1143, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Antonin Morillon 3 Non Coding RNA, Epigenetic and Genome Fluidity, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Antonin Morillon Boris Bardot 1 Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; 5 Signaling and Neural Crest Development, Institut Curie, CNRS UMR3347, INSERM U1021, Université Paris-Saclay, PSL University , Orsay, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Boris Bardot For correspondence: franck.toledo{at}sorbonne-universite.fr boris.bardot{at}curie.fr Franck Toledo 1 Genetics of Tumor Suppression, Institut Curie, CNRS UMR3244, Sorbonne University, PSL University , Paris, France ; 6 Hematopoietic and Leukemic Development, Centre de Recherche Saint-Antoine, INSERM UMRS938, Sorbonne University , Paris, France ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Franck Toledo For correspondence: franck.toledo{at}sorbonne-universite.fr boris.bardot{at}curie.fr Abstract Full Text Info/History Metrics Preview PDF Abstract Missense “hotspot” mutations localized in six p53 codons account for 20% of TP53 mutations in human cancers. Hotspot p53 mutants have lost the tumor suppressive functions of the wildtype protein, but whether and how they may gain additional functions promoting tumorigenesis remain controversial. Here we generated Trp53 Y217C , a mouse model of the human hotspot mutant TP53 Y220C . DNA damage responses were lost in Trp53 Y217C/Y217C cells, and Trp53 Y217C/Y217C fibroblasts exhibited increased chromosome instability compared to Trp53 -/- cells. Furthermore, Trp53 Y217C/Y217C male mice died earlier than Trp53 -/- males, with more aggressive thymic lymphomas. This correlated with an increased expression of inflammation-related genes in Trp53 Y217C/Y217C thymic cells compared to Trp53 -/- cells. Surprisingly, we recovered only one Trp53 Y217C/Y217C female for 22 Trp53 Y217C/Y217C males at weaning, a skewed distribution explained by a high frequency of Trp53 Y217C/Y217C female embryos with exencephaly and the death of most Trp53 Y217C/Y217C female neonates. Strikingly however, when we treated pregnant females with the anti-inflammatory drug supformin (LCC-12) we observed a five-fold increase in the proportion of viable Trp53 Y217C/Y217C weaned females in their progeny. Together, these data suggest that the p53 Y217C mutation not only abrogates wildtype p53 functions but also promotes inflammation, with oncogenic effects in males and teratogenic effects in females. Introduction Somatic alterations in the TP53 gene, encoding the tumor suppressor p53, are the most common events in human tumors ( Hollstein et al., 1991 ). The p53 protein is a stress sensor stabilized and activated in response to potentially oncogenic insults. In its tetrameric active form, wildtype (WT) p53 can trigger a transcriptional program to induce various responses including cell cycle arrest, senescence, apoptosis or metabolic changes ( Beckerman and Prives, 2010 ). In human cancers, about 75% of all TP53 alterations are missense mutations, and the eight most frequent (“hotspot”) missense mutations (R175H, Y220C, G245S, R248Q, R248W, R273H, R273C and R282W) affect six residues localized in the p53 DNA-binding domain (DBD) and account for 20% of all TP53 mutations ( Hainaut and Pfeifer, 2016 ). The fact that most TP53 mutations are missense substitutions suggested that cells expressing mutant p53 might have a selective advantage over cells lacking p53, and evidence for this was first gained by expressing various p53 mutants in p53-null cells and observing enhanced tumorigenic potential in nude mice or increased plating efficiency in agar cell culture ( Dittmer et al., 1993 ). Mouse models expressing hotspot p53 mutants next helped to define potential mechanisms accounting for accelerated tumorigenesis. First, a dominant-negative effect (DNE) may be observed in heterozygotes, if the mutant p53 inhibits the WT p53 protein in hetero-tetramers ( Gencel-Augusto and Lozano, 2020 ). Evidence that this mechanism accounts for accelerated tumorigenesis was notably reported in human leukemia ( Boettcher et al., 2019 ). A second mechanism is a gain-of-function (GOF), i.e. the acquisition by mutant p53 of new oncogenic properties ( Amelio and Melino, 2020 ; Stein et al., 2020 ). Although the DNA sequence specificity of p53 mutants is impaired, leading to a loss of WT functions (LOF), many p53 mutant proteins are stabilized in the cell and might engage in aberrant interactions with other transcription factors, chromatin-modifying complexes or DNA helicase subunits, leading to the acquisition of GOF phenotypes ( Kim and Deppert, 2007 ; Pfister and Prives, 2017 ; Zhao et al., 2024 ). However, a few recent studies challenged the pathological importance of mutant p53 GOF, or at least its relevance in anti-cancer therapeutic strategies ( Aubrey et al., 2018 ; Boettcher et al., 2019 ; Wang et al., 2023 ). An alternative hypothesis emerged, postulating that the tumorigenic properties of a p53 mutant might result from a separation-of-function (SOF), if the mutant retains pro-proliferative or pro-survival functions of WT p53 while losing its tumor suppressive activities ( Kennedy and Lowe, 2022 ). The concept of SOF was first proposed for TP53 exon-6 truncating mutations, which mimic a naturally occurring alternative p53 splice variant ( Shirole et al., 2016 ), but may apply to some p53 missense mutations, for example p53 R248W ( Humpton et al., 2018 ). Importantly, the analysis of various mutant p53 alleles in vivo appears crucial for a better understanding of their contribution to tumorigenesis, because GOF/SOF phenotypes may vary depending on the mutated residue, its specific mutation, the cellular context or genetic background ( Dibra et al., 2024 ; Hanel et al., 2013 ; Kadosh et al., 2020 ; Kim and Lozano, 2018 ; Kotler et al., 2018 ; McCann et al., 2022 ; Xiong et al., 2022 ). In human cancers, the TP53 Y220C mutation is the most frequent missense mutation outside of the DNA-binding surface of p53 ( Hainaut and Pfeifer, 2016 ). The somatic TP53 Y220C mutation accounts for over 100,000 new cancer cases per year worldwide, including solid tumors and myeloid neoplasms, and a germline TP53 Y220C mutation was reported in 15 families with the Li-Fraumeni syndrome (LFS) of cancer predisposition ( Bouaoun et al., 2016 ; Gener-Ricos et al., 2024 ). The mutation causes a structural change in the DBD localized at the periphery of the β-sandwich region of the protein, far from the surface contact of DNA. The mutation from a tyrosine to a cysteine markedly lowers the thermodynamic stability of the DBD, leading to a largely unfolded and inactive protein at body temperature ( Joerger et al., 2006 ), and a molecule designed to bind p53 Y220C and restore WT protein conformation appears as a promising anti-cancer drug ( Dumbrava et al., 2022 ). Analyses of the impact of p53 Y220C in cancer cell lines led to conflicting results. On one hand, overexpression of p53 Y220C in a p53-null cell line increased its capacity for migration or invasion ( Zhou et al., 2022 ), and a decreased expression of p53 Y220C , caused by RNA interference or various chemical compounds, promoted cell death or decreased the migratory or invasive capacities of cells ( Tseng et al., 2022 ; Vikhanskaya et al., 2007 ; Zhou et al., 2022 ). On the other hand, the removal by CRISPR/Cas9 of p53 mutants with reported GOF - including p53 Y220C - in diverse cancer cell lines had no significant impact on cell survival or proliferation, and the cell death caused by RNA interference against p53 Y220C might result from non-specific toxic effects ( Wang et al., 2023 ). Here, to gain a better understanding of the impact of the p53 Y220C mutation in vivo , we generated a mouse model with a targeted Trp53 Y217C mutation - the mouse equivalent to human TP53 Y220C ( Figure S1 ) - and analyzed animals and cells carrying one or two copies of the mutant allele. Results Targeting of a p53 Y217C mutation in the mouse We used homologous recombination in 129/SvJ ES cells to target the p53 Y217C mutation at the mouse Trp53 locus. Mice expressing p53 Y217C conditionally were generated by using a targeting vector containing transcriptional stops flanked by LoxP sites (LSL) upstream of coding sequences, and the p53 Y217C mutation in exon 6 ( Figure 1A-D ). Trp53 +/LSL-Y217C mice were then crossed with mice carrying the PGK-Cre transgene ( Lallemand et al., 1998 ) to excise the LSL cassette and obtain Trp53 +/Y217C mice, expressing the mutant protein constitutively. After two backcrosses over a C57BL/6J background, we prepared mouse embryonic fibroblasts (MEFs) from intercrosses of Trp53 +/Y217C mice ( Figure 1E ). We extracted RNAs from Trp53 Y217C/Y217C MEFs then sequenced p53 mRNAs to verify that the p53 Y217C coding sequence was identical to the wildtype p53 (p53 WT ) sequence, except for the desired missense mutation and a silent mutation introduced to facilitate mouse genotyping ( Figure 1F ). The quantification of p53 mRNA levels from WT and Trp53 Y217C/Y217C MEFs next revealed similar transcription from both alleles ( Figure 1G ). Download figure Open in new tab Figure 1. Targeting the Y217C missense mutation at the mouse Trp53 locus. (A) Targeting strategy. The wildtype (WT) Trp53 gene is within a 17 kb-long EcoRI (RI) fragment (black boxes are for coding sequences and white boxes for UTRs). The targeting construct contains: (1) a 1.5 kb-long 5’ homology region; (2) a Lox-Stop-Lox (LSL) cassette with a neomycin selection gene (Neo), four transcriptional stops (STOP) and an EcoRI site, flanked by LoxP sites (arrowheads); (3) p53 coding exons, including the Y217C (YC) missense mutation in exon 6 (asterisk) and an additional BanII site; (4) a 2.8 kb-long 3’ homology region; and (5) the diphteria α-toxin (DTA) gene for targeting enrichment. Proper recombinants with a Trp53 LSL-Y217C allele, resulting from the described crossing-overs, were G418 resistant. They were identified by a 2.4 kb-long band after PCR with primers a and b, and confirmed by bands of 635 and 224 bp after PCR with primers c and d and BanII digestion. They were also verified by Southern blot with the indicated probe as containing a 10.5 kb EcoRI band. Two recombinant ES clones were injected into blastocysts to generate chimeras, and germline transmission was verified by genotyping with primers c and d and BanII digestion. Excision of the LSL cassette was performed in vivo , by breeding Trp53 +/LSL-Y217C male mice with females carrying the PGK- Cre transgene, to obtain mice with a Trp53 Y217C allele. (B-D) Screening of recombinant ES clones (+) by PCR with primers a and b (B); PCR with primers c and d then BanII digestion (C); Southern blot (D). (E) Genotyping of mouse embryonic fibroblasts (MEFs) from an intercross of Trp53 +/Y217C mice, by PCR with primers c and d and BanII digestion. (F) Trp53 Y217C sequence around codon 217. The introduced Y217C missense mutation and the silent mutation creating an additional BanII restriction site are highlighted (asterisks). (G) WT and Trp53 Y217C/Y217C (YC/YC) MEFs express similar p53 mRNA levels. Total RNA was extracted, then p53 mRNAs were quantified by real-time qPCR, normalized to control mRNAs and the amount in WT cells was assigned the value of 1. Primer sequences are listed in Table S8 . Deficient p53-dependent stress responses in Trp53 Y217C/Y217C cells We used western blots to analyze protein extracts from Trp53 +/+ , Trp53 +/- , Trp53 +/Y217C , Trp53 Y217C/Y217C and Trp53 -/- MEFs, unstressed or treated with Nutlin, an antagonist of Mdm2, the E3 ubiquitin ligase for p53 ( Vassilev et al., 2004 ). Results indicated a high increase in p53 abundance in untreated and Nutlin-treated Trp53 Y217C/Y217C MEFs and a moderate increase in untreated and Nutlin-treated Trp53 +/Y217C MEFs, compared to WT cells ( Figures 2A and S2 ). Protein levels for p21 and Mdm2, the products of two classical p53 target genes, appeared similar in Trp53 +/+ and Trp53 +/Y217C MEFs, and were undetectable or markedly decreased in Trp53 Y217C/Y217C and Trp53 -/- MEFs ( Figures 2A and S2 ). Accordingly, p53 Y217C appeared unable to transactivate the Cdkn1a/p21 and Mdm2 genes or to bind their promoters ( Figure 2B ). The fractionation of cells before or after treatment with doxorubicin, a clastogenic drug, indicated that p53 WT accumulated in the nucleoplasm and chromatin fractions in response to DNA damage, whereas p53 Y217C appeared mostly cytoplasmic in both untreated and doxorubicin-treated cells, and undetectable or barely detectable in chromatin fractions ( Figures 2C and S3 ). Furthermore, when Nutlin-treated MEFs were analyzed by immunofluorescence, p53 WT was only detected in nuclei, whereas p53 Y217C could be observed in nuclear and cytoplasmic compartments ( Figure 2D ). We next analyzed two well-known p53-mediated responses to DNA damage, i.e. cell cycle arrest in MEFs and apoptosis in thymocytes ( Kastan et al., 1992 ; Lowe et al., 1993 ). WT MEFs exposed to increasing doses of ɣ-irradiation (3 Gy or 12 Gy) exhibited significant increases in G1/S ratios, whereas G1/S ratios were similar before or after irradiation in Trp53 Y217C/Y217C and Trp53 -/- MEFs ( Figures 2E and S4 ). Furthermore, thymocytes recovered from irradiated WT mice underwent a massive apoptotic response, with an almost three-fold increase in apoptotic cells after a 10 Gy irradiation. By contrast, no increase in apoptotic cells was observable upon irradiation in the thymi from Trp53 Y217C/Y217C mice, and apoptotic thymocytes were equally rare in irradiated Trp53 Y217C/Y217C and Trp 53 -/- mice ( Figures 2F and S5 ). Together, these results indicated that the p53 Y217C mutation altered the abundance and intracellular distribution of the p53 protein, associated with a decrease in DNA-bound protein, and that p53 Y217C had completely lost the ability to induce cell cycle arrest and apoptosis upon DNA damage. Download figure Open in new tab Figure 2. Trp53 Y217C/Y217C cells exhibit alterations in p53 abundance and subcellular localization, defective responses to DNA damage, and increased chromosomal instability. (A) Increased p53 protein levels in Trp53 Y217C/Y217C and Trp53 +/Y217C MEFs. MEFs of the indicated genotypes were treated or not with 10 μM Nutlin 3a for 24 h, then protein extracts were immunoblotted with antibodies against Mdm2, p53, p21 and actin. (B) The transactivation of classical p53 target genes Cdkn1a/p21 and Mdm2 is impaired in Trp53 Y217C/Y217C cells. WT, Trp53 Y217C/Y217C and Trp53 -/- MEFs were treated as in (A), then (top) mRNAs were quantified in 5-6 independent experiments using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in unstressed WT cells assigned a value of 1; or (bottom) ChIP assays were performed at the Cdkn1a and Mdm2 promoters in 2-3 independent experiments with an antibody against p53 or rabbit IgG as a negative control. Immunoprecipitates were quantified using real-time PCR, normalized to data over an irrelevant region, and the amount in unstressed WT cells was assigned a value of 1. (C) Assessment of p53 WT and p53 Y217C subcellular localization by cellular fractionation. WT and Trp53 Y217C/Y217C MEFs were treated or not with 1 μM doxorubicin (Doxo) for 24 hr, submitted to cellular fractionation, then protein extracts were immunoblotted with antibodies against p53 or the fraction controls Tubulin for cytoplasm (Cp.), Nup98 for nucleoplasm (Np.) and histone H3 for chromatin (χin). (D) Assessment of p53 WT and p53 Y217C subcellular localization by immunofluorescence. WT, Trp53 Y217C/Y217C and Trp53 -/- MEFs were treated with 10 μM Nutlin 3a for 24 h, then stained with antibodies against p53 (red) or actin (green) and DNA was counterstained with DAPI (blue). (E) Absence of a cell cycle arrest response in Trp53 Y217C/Y217C MEFs. Asynchronous cell populations of Trp53 +/+ , Trp53 Y217C/Y217C and Trp53 -/- MEFs were analyzed 24 hr after 0, 3 or 12 Gy ɣ-irradiation. Results from 3 independent experiments. (F) Absence of a p53-dependent apoptotic response in Trp53 Y217C/Y217C thymocytes. Age-matched mice of the indicated genotypes were left untreated or submitted to 10 Gy whole-body ɣ-irradiation then sacrificed after 4 hr and their thymocytes were stained with Annexin V-FITC and analyzed by FACS, in 2 independent experiments. (G) Increased chromosomal instability in Trp53 Y217C/Y217C fibroblasts. Metaphase spreads were prepared from WT, Trp53 Y217C/Y217C and Trp53 -/- MEFs at passage 4, then aberrant metaphases (with chromosome breaks, radial chromosomes or DMs) were scored. Left: distribution of aberrant metaphases. Data from 110 WT, 97 Trp53 Y217C/Y217C or 119 Trp53 -/- complete diploid metaphases, independently observed by two experimenters. Right: examples of two aberrant Trp53 Y217C/Y217C metaphases: one with a double minute chromosome (DM), a chromosome break (Br) and a radial chromosome (R), the other with multiple DMs. Enlargements of regions of interest are presented between the two metaphases. Scale bars (D, G): 5 μm. ***P<0.001, **P<0.01, *P<0.05, °P=0.09, ns: non-significant by Student’s t (B, E, F) or Fischer’s (G) tests. Increased chromosomal instability in Trp53 Y217C/Y217C cells We next searched for evidence, at the cellular level, of potential dominant negative effect (DNE) or gain of function (GOF) for the p53 Y217C mutant. Little if any difference in the transactivation of canonical p53 target genes was observed between WT, Trp53 +/Y217C and Trp53 +/- cells treated with Nutlin or Doxorubicin ( Figure S6A ), and Trp53 +/Y217C and Trp53 +/- cells exhibited similar cell cycle arrest or apoptotic responses to γ-irradiation ( Figure S6B-C ), suggesting little or no DNE in response to various stresses. On the opposite, we obtained clear evidence of a GOF for the p53 Y217C mutant. Two p53 mutants (p53 G245D and p53 R273H ) were recently proposed to promote tumorigenesis by predisposing cells to chromosomal instability ( Zhao et al., 2024 ), which led us to compare the frequency of chromosome rearrangements in WT, Trp53 Y217C/Y217C and Trp 53 -/- primary MEFs. We searched for chromosome breaks, radial chromosomes, or double-minute chromosomes (DMs) in preparations of MEFs treated with the anti-mitotic nocodazole for metaphase enrichment. The three categories of chromosome rearrangements were more frequently observed in Trp53 Y217C/Y217C MEFs than in Trp 53 -/- or WT cells ( Figure 2G ), indicating a GOF that promotes chromosomal instability. Impact of p53 Y217C on mouse development We next determined the impact of the p53 Y217C mutation in vivo , by comparing mouse cohorts generated from intercrosses of heterozygous Trp53 +/- or Trp53 +/Y217C mice resulting from ≥ 5 backcrosses to the C57BL6/J background. Intercrosses of Trp53 +/- mice are known to yield a reduced proportion of Trp53 -/- mice, that is mainly due to defects in neural tube closure causing exencephaly in a fraction of Trp53 -/- female embryos ( Armstrong et al., 1995 ; Sah et al., 1995 ) and, to a lesser extent, to lung dysfunction affecting a fraction of Trp53 -/- neonates ( Tateossian et al., 2015 ). At weaning (on the 21 st day postpartum or P21), we observed one Trp53 -/- female mouse for 3.5 p53 -/- males from Trp53 +/- intercrosses, an underrepresentation of females consistent with frequencies reported in earlier studies ( Armstrong et al., 1995 ; Sah et al., 1995 ). Strikingly, the underrepresentation of weaned females was even more acute for Trp53 Y217C/Y217C mice, with only one Trp53 Y217C/Y217C female for 19 Trp53 Y217C/Y217C males from Trp53 +/Y217C intercrosses ( Figure 3A ). We next analyzed Trp53 Y217C/Y217C embryos generated from heterozygous intercrosses or from heterozygous-homozygous ( Trp53 +/Y217C x Trp53 Y217C/Y217C ) crosses, at embryonic days E12.5-E16.5. An underrepresentation of Trp53 Y217C/Y217C female embryos was not observed, but 11/26 (42%) female embryos exhibited developmental abnormalities, including 10 with exencephaly, whereas all the male embryos appeared normal ( Figure 3B ). Importantly, the frequency of Trp53 Y217C/Y217C female embryos with exencephaly (38.5%) was much higher than the reported frequency (0-8%) of Trp53 -/- female embryos with exencephaly of C57BL/6 x 129/Sv genetic background ( Donehower et al., 1992 ; Sah et al., 1995 ), suggesting a stronger effect of the p53 Y217C mutant on female embryonic development. Download figure Open in new tab Figure 3. Trp53 Y217C/Y217C mice exhibit female-specific perinatal lethality. (A) Distribution of weaned mice obtained from Trp53 +/- or Trp53 +/Y217C intercrosses. Obs: observed numbers of mice at weaning (P21); exp: expected numbers assuming a Mendelian distribution without sex distortion; f/m: observed female/male ratios. Consistent with previous reports, the observed distribution of weaned mice from Trp53 +/- intercrosses did not conform to values expected for a Mendelian distribution without sex distortion (υ=5; χ 2 =16.31>15.09), indicating a significant deficit in female Trp53 -/- mice (top). The distribution of weaned mice from Trp53 +/Y217C intercrosses diverged even more from values for a Mendelian distribution without sex distortion (υ =5; χ 2 =104.23>15.09), due to a striking deficit in female Trp53 Y217C/Y217C mice (bottom). Differences between the frequencies of Trp53 Y217C/Y217C (4/677) and Trp53 -/- (8/196) females in the progeny, or between the female to male ratios for Trp53 Y217C/Y217C (4/75) and Trp53 -/- (8/28) animals, are statistically significant (P=0.0012 and P=0.0087 in Fischer’s tests, respectively). (B) Exencephaly is frequently observed in p53 Y217C/Y217C female embryos. Top: the distribution of E12.5-16.5 embryos from heterozygous ( Trp53 +/Y217C ) intercrosses or heterozygous-homozygous ( Trp53 +/Y217C x Trp53 Y217C/Y217C ) crosses is shown. f or m exenc.: number of female or male embryos with exencephaly; o.a.: embryos with other abnormalities. Below, examples of female Trp53 Y217C/Y217C embryos at E12.5, 13.5 and 16.5 exhibiting exencephaly (arrows) are each shown (center) together with a normal embryo from the same litter (bottom). (C) Distribution of mice at birth from the indicated crosses. Of note, out of five Trp53 Y217C/Y217C females observed at birth, only one remained alive at weaning age. Thus, the female/male ratio for weaned Trp53 Y217C/Y217C animals from these crosses was 1/22, a ratio similar to the one observed in A (4/75). In Trp53 -/- female mice, exencephaly was previously correlated with stochastic aberrant X chromosome inactivation, with a decreased expression of Xist and an increase in bi-allelic expression of X-linked genes including Maob , Pls3 and Usp9x ( Delbridge et al., 2019 ). We prepared neurospheres from Trp53 +/+ , Trp53 -/- and Trp53 Y217C/Y217C female embryos and quantified mRNAs for these genes in neurospheres. Compared to neurospheres from WT animals, Trp53 Y217C/Y217C and Trp53 -/- neurospheres exhibited an apparent decrease in Xist expression and significantly higher levels of Maob , Pls3 and Usp9x ( Figure S7 ). Thus, as for female Trp53 -/- mice, aberrant chromosome X inactivation may contribute to the underrepresentation of Trp53 Y217C/Y217C female mice. Of note however, defects in chromosome X inactivation did not appear more pronounced in Trp53 Y217C/Y217C neurospheres than in Trp53 -/- neurospheres. To further analyze the impact of the p53 Y217C mutation during development, we also determined its potential effect in embryos lacking Mdm2 or Mdm4, two major p53 regulators. The embryonic lethality resulting from Mdm2 or Mdm4 loss is rescued by a concomitant p53 deficiency ( Bardot et al., 2015 ; Finch et al., 2002 ; Jones et al., 1995 ; Migliorini et al., 2002 ; Montes de Oca Luna et al., 1995 ; Parant et al., 2001 ). This provides a powerful assay for analyzing the functionality of p53 mutant alleles ( Bardot et al., 2015 ; Iwakuma et al., 2004 ; Marine et al., 2006 ; Toledo et al., 2006 ). We identified Mdm2 -/- Trp53 Y217C/Y217C and Mdm4 -/- Trp53 Y217C/Y217C viable mice of both sexes, consistent with a major loss of canonical WT p53 activities in the p53 Y217C mutant ( Table S1 ). Of note, in these experiments we mated Mdm4 +/- Trp53 +/Y217C mice with Mdm4 +/- Trp53 Y217C/Y217C mice, or Mdm2 +/- Trp53 +/Y217C mice with either Mdm2 -/- Trp53 Y217C/Y217C or Mdm2 +/- Trp53 Y217C/Y217C animals, to analyze the progeny at weaning. No Trp53 Y217C/Y217C female mouse was recovered from these crosses, whereas 14 Trp53 Y217C /Y217C males were obtained, again demonstrating a striking deficit in Trp53 Y217C/Y217C females at weaning. Among animals lacking one or two copies of either Mdm2 or Mdm4 , we also observed a deficit in Trp53 Y217C/Y217C weaned females. However, the female to male ratio for Trp53 Y217C/Y217C animals appeared markedly increased in genetic backgrounds with Mdm4 haploinsufficiency (4/15) or loss (1/6), but only marginally increased (if at all) in genetic backgrounds with Mdm2 haploinsufficiency (1/11) or loss (1/11). This suggested that altering the levels of p53 inhibitors, particularly Mdm4, might improve the survival of Trp53 Y217C/Y217C females ( Table S1 ). The high frequency (42%) of abnormal Trp53 Y217C/Y217C female embryos at E12.5-E16.5 could only partially account for the acute deficit in Trp53 Y217C/Y217C females observed at weaning, suggesting either embryonic abnormalities undetectable macroscopically, or that a fraction of Trp53 Y217C/Y217C females died later in development or postpartum. We performed additional crosses to analyze female to male ratios at postpartum day 0 or 1 (P0-P1) and observed 20 females for 18 males for Trp53 +/+ animals, but only five females for 22 males for Trp53 Y217C/Y217C animals ( Figure 3C ). Furthermore, only one of these Trp53 Y217C/Y217C females reached weaning age, and the four other neonates died before P2. Altogether, these data led to conclude that the p53 Y217C mutation caused female-specific developmental abnormalities at a higher penetrance than a null allele, leading to a perinatal (late embryonic or early postpartum) lethality for most homozygous mutant females. Interestingly, we observed that Trp 53 Y217C/Y217C males were fertile and included them in some of our crosses to generate homozygous mutants at higher frequencies ( Figure 3B-C ). By contrast, we were able to mate two Trp53 Y217C/Y217C adult females with a Trp53 +/Y217C male, and both got pregnant but had to be euthanized due to complications while giving birth. In both cases, extended labor (> 24 hr) was the main sign of dystocia ( Table S2 ). These observations suggest that, even for the rare Trp53 Y217C/Y217C females able to reach adulthood, the p53 Y217C mutation caused pathological traits not observed in Trp53 -/- females, because the loss of p53 was not previously reported to cause dystocia ( Embree-Ku and Boekelheide, 2002 ; Guimond et al., 1996 ; Hu et al., 2007 ). Together, our data indicated that the p53 Y217C mutation not only abolished canonical p53 activities, but also conferred additional effects compromising female perinatal viability or parturition. Impact of p53 Y217C on tumorigenesis We next analyzed the impact of the p53 Y217C mutation on the onset and spectrum of spontaneous tumors in mice. We first compared Trp53 +/Y217C , Trp53 +/- and Trp53 +/+ mouse cohorts for 2 years. Trp53 +/Y217C and Trp53 +/- cohorts exhibited similar spontaneous tumor onset and spectrum, with most mice developing sarcomas during their second year of life ( Figure S8 ). Thus, at least for tumors arising spontaneously, the p53 Y217C mutant protein did not appear to exert a DNE over the wildtype p53 protein. We next compared Trp53 Y217C/Y217C and Trp53 -/- mouse cohorts. Because of the difficulty to generate Trp53 Y217C/Y217C females, we restricted our comparison to males, to avoid potential biases that might result from different sex ratios. All Trp53 -/- mice are known to die in less than 1 year, from thymic lymphomas in most cases, or more rarely from sarcomas ( Donehower et al., 1992 ; Jacks et al., 1994 ). Trp53 Y217C/Y217C males died faster than their Trp53 -/- counterparts: all the Trp53 Y217C/Y217C males were dead by the age of 7 months, whereas more than 20% of the Trp53 -/- males were still alive at that age ( Figure 4A ). Furthermore, most Trp53 -/- and Trp53 Y217C/Y217C mice died from thymic lymphomas, but histological analysis of tumor organs revealed that the lymphomas in Trp53 Y217C/Y217C males were more aggressive and invasive, with sites of metastases notably including the lungs, spleen, liver or kidneys ( Figures 4B-C and S9 ). Thus, the p53 Y217C mutation not only abolished canonical tumor suppressive activities but also apparently conferred oncogenic properties to the encoded protein. Consistent with this, when we performed an RNA-seq analysis of thymi from 8 weeks-old Trp53 +/+ , Trp53 -/- and Trp53 Y217C/Y217C males, 81.5 % of the 717 differentially expressed genes indicated a loss of function (LOF) in the p53 Y217C mutant, but genes suggesting a GOF or a separation of function (SOF) were also observed ( Figure S10A and Table S3 ). Of note, among the differentially expressed genes corresponding to a LOF in the p53 Y217C mutant were Bbc3/Puma , Cdkn1a/p21 and Zmat3 ( Figure S10B ), three p53-target genes known to play major roles in p53-mediated tumor suppression ( Brennan et al., 2023 ). Download figure Open in new tab Figure 4. Oncogenic effects of the mutant protein in Trp53 Y217C/Y217C male mice. (A-B) In homozygous males, p53 Y217C leads to accelerated tumor-induced death (A), and aggressive metastatic tumors (B); n=cohort size. (C) Hematoxylin and eosin (H&E) staining of sections from the lung (top) and spleen (bottom) of Trp53 -/- and Trp53 Y217C/Y217C male mice, showing metastases in Trp53 Y217C/Y217C animals. Normal organ structures are shown, with “A” indicating pulmonary alveoli, and “WP” and “RP” standing for splenic white and red pulp, respectively. In the lung section of the Trp53 Y217C/Y217C mouse, the rectangle indicates a lymphoma area. In the spleen section of the Trp53 Y217C/Y217C mouse, the typical splenic structures are absent due to massive tissue homogenization of the spleen by lymphoma cells. We next performed a comparative analysis focusing on Trp53 Y217C/Y217C and Trp53 -/- thymi, which revealed 192 differentially expressed genes ( Figure 5A-B and Table S4 ). An analysis of these data with GOrilla, the Gene Ontology enRIchment anaLysis and visuaLizAtion tool ( Eden et al., 2009 ), indicated that 141 of these genes were associated with at least one gene ontology (GO) term, and revealed a significant enrichment for genes associated with white blood cell chemotaxis/migration and inflammation ( Figures 5C and S11 ). Among these genes were notably Ccl17 , Ccl9 , Ccr3 , Cxcl10 , S100a8 and S100a9 , six genes associated each with 10-15 GO terms related to white blood cell behavior and inflammation ( Table S5 ). We next used RT-qPCR to quantify the expression of these genes in thymi from 8 weeks-old Trp53 +/+ , Trp53 Y217C/Y217C and Trp53 -/- male mice. Their expression was significantly increased in Trp53 Y217C/Y217C thymic cells compared to Trp53 -/- , or to both Trp53 +/+ and Trp53 -/- cells, consistent with gain or separation of function (GOF/SOF) effects in the Trp53 Y217C mutant ( Figure 5D ). We also compared the transcriptomes of Trp53 Y217C/Y217C and Trp53 -/- thymocytes by gene set enrichment analysis ( Subramanian et al., 2005 ). We found 13 gene sets significantly enriched in Trp53 Y217C/Y217C cells with normalized enrichment scores (NES) > 2, among which three (“antimicrobial peptides”, “chemokine receptors bind chemokines” and “defensins”) were related to immunity ( Figures 5E and S12A ), consistent with an inflammatory response associated with the p53 Y217C mutant. Other enriched gene sets notably included five sets (“electron transport chain”, “respiratory electron transport ATP synthesis by chemiosmotic coupling and heat production by uncoupling proteins”, “mitochondrial translation”, “respiratory electron transport” and “oxidative phosphorylation”) related to mitochondria function, and three sets (“deposition of new CENPA-containing nucleosomes at the centromere”, “arginine methyltransferases methylate histone arginines” and “PRC2 methylates histones and DNA”) related to chromatin plasticity ( Figures 5E and S12B-C ). These gene sets, differentially expressed between Trp53 Y217C/Y217C and Trp53 -/- cells, might contribute to accelerated tumorigenesis in Trp53 Y217C/Y217C mice, given the reported impact of inflammation, metabolism changes and epigenetic plasticity on cancer evolution ( Feinberg et al., 2006 ; Greten and Grivennikov, 2019 ; Kroemer and Pouyssegur, 2008 ). Furthermore, the hotspot mutants p53 G245D or p53 R273H were recently proposed to promote tumor progression by inducing non-canonical nuclear factor kappa light chain enhancer of activated B cell (NC-NF-κB) signaling ( Zhao et al., 2024 ). In Trp53 Y217C/Y217C cells, one gene set related to NC-NF-κB (“Dectin 1-mediated non-canonical NF-κB signaling”) was significantly enriched and two other NF-κB-related gene sets were also potentially enriched ( Figure 5F and S13 ). Download figure Open in new tab Figure 5. Evidence of inflammation in Trp53 Y217C/Y217C mice. (A-B) RNAseq analysis of thymi from Trp53 Y217C/Y217C (n=3) and Trp53 -/- (n=3) 8 weeks-old male mice. Volcano plot (A), with differentially expressed genes (DEGs), downregulated (blue) or upregulated (red) in Trp53 Y217C/Y217C cells. Unsupervised clustering heat-map plot (B), with 192 DEGs ranked according to log 2 fold changes. (C) Gene Ontology (GO) analysis of DEGs. Out of 192 DEGs, 141 are associated with at least one GO term, according to the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla). For each GO term, enrichment was calculated by comparing with the full list of 19759 genes associated with a GO term, and results are presented here with a color scale according to P-value of enrichment. This analysis mainly revealed an enrichment for genes associated with white blood cell chemotaxis/migration and inflammation, as shown here. Complete results of the analysis are presented in Figure S11 . (D) RT-qPCR analysis of the indicated genes in thymi from 8 weeks-old Trp53 +/+ , Trp53 Y217C/Y217C and Trp53 -/- male mice. Means + s.e.m. (n=3 per genotype). ***P<0.001, **P<0.01, *P<0.05, °P<0.075 by Student’s t test. (E) Gene set enrichment analysis (GSEA) of transcriptomes from Trp53 Y217C/Y217C and Trp53 -/- thymic cells. GSEA identified 13 gene sets enriched in Trp53 Y217C/Y217C cells with normalized enrichment scores (NES) > 2. Nominal p-values (NOM p-val) and false discovery rate q-values (FDR q-val) are indicated. (F) GSEA provides evidence of increased NC-NF-kB signaling in Trp53 Y217C/Y217C male thymocytes. Results are presented as in E. (G) Supformin (LCC-12), an anti-inflammatory molecule, increases the female to male ratio in Trp53 Y217C/Y217C weaned pups. Trp53 +/Y217C females were mated with Trp53 Y217C/Y217C males, then oral gavage of pregnant females with 5 mg/kg supformin was performed on the 10 th and 11 th days post-coitum, and their progeny was genotyped at weaning. The female to male (f/m) ratio for Trp53 Y217C/Y217C weaned pups that were exposed to supformin in utero (+) was compared to the f/m ratios for Trp53 -/- or Trp53 Y217C/Y217C weaned pups never exposed to supformin (-). Exposure to supformin led to a five-fold increase in the proportion of Trp53 Y217C/Y217C weaned females. **P<0.01, °P=0.056, ns: non-significant by Fischer’s test. Reducing inflammation may rescue a fraction of female Trp53 Y217C/Y217C embryos Our data indicated that inflammation correlated with accelerated tumorigenesis in Trp53 Y217C/Y217C male mice. Interestingly, inflammation was previously proposed to promote neural tube defects or embryonic death in a few mouse models ( Lian et al., 2004 ; McNairn et al., 2019 ; Zhao et al., 2013 ). Furthermore CD44 , encoding a cell-surface glycoprotein that drives inflammation and cancer progression ( Solier et al., 2023 ), was recently identified as a key gene for the diagnosis and early detection of open neural tube defects ( Karthik et al., 2022 ). Together, these data led us to hypothesize that, at least in a fraction of Trp53 Y217C/Y217C females, neural tube defects might result from inflammation. To test this hypothesis, we mated Trp53 +/Y217C female mice with Trp53 Y217C/Y217C males, then administered supformin to pregnant females by oral gavage. Supformin (LCC-12), a potent inhibitor of the CD44-copper signaling pathway, was shown to reduce inflammation in vivo ( Solier et al., 2023 ). Without any treatment, our previous crosses ( Figure 3 and Table S1 ) collectively yielded a female to male ratio of 0.045 for Trp53 Y217C/Y217C weaned mice (f/m=5/111 [4+1+0+0]/[75+22+9+5]), significantly different from the ratio of 0.29 (f/m=8/28) for Trp53 -/- weaned animals. By contrast, in the progeny of supformin-treated pregnant mice we observed a five-fold increase in the female to male ratio for Trp53 Y217C/Y217C weaned animals, to reach a value of 0.23 (f/m=3/13) indistinguishable from the ratio in Trp53 -/- weaned animals from untreated mice ( Figure 5G and Table S6 ). This result suggests that reducing inflammation in developing Trp53 Y217C/Y217C female embryos may increase their viability. Discussion In this report, we generated a mouse model with a Trp53 Y217C allele, the murine equivalent of the human hotspot mutant TP53 Y220C . The analysis of this mouse model indicated that the p53 Y217C mutation leads to the loss of many canonical wildtype p53 activities, notably the capacity to transactivate target genes important for tumor suppression (e.g. Bbc3 , Cdkn1a and Zmat3 ). The fact that p53 Y217C can rescue the embryonic lethality caused by a deficiency in Mdm2 or Mdm4 is also consistent with a major loss of canonical wildtype p53 functions (LOF) in this mutant. These findings are consistent with the notion that hotspot p53 mutants cause a complete or near complete LOF ( Funk et al., 2025 ). In addition, our analyses provide evidence that the p53 Y217C mutation exhibits oncogenic effects. The possibility that a mutant p53 might acquire oncogenic functions was first suggested over 30 years ago ( Dittmer et al., 1993 ), but this notion became controversial in recent years. Indeed, studies of a few p53 mutants in human acute myeloid leukemia and a mouse model of B cell lymphoma indicated that their increased tumorigenicity might result from dominant-negative effects (DNE) rather than gain of function (GOF), and a recent study further suggested that the putative GOF of many p53 mutants would not be required to sustain the expansion of tumors ( Aubrey et al., 2018 ; Boettcher et al., 2019 ; Wang et al., 2023 ). Here, however, we observed accelerated tumorigenesis in Trp53 Y217C/Y217C mice, but did not observe any evidence of DNE for spontaneous tumorigenesis in Trp53 +/Y217C animals. Importantly, the fact that p53 Y217C did not exhibit a DNE over the WT protein is consistent with the report that Li-Fraumeni patients carrying an heterozygous TP53 Y220C mutation display a similar age of cancer onset than Li-Fraumeni patients with an heterozygous non-sense TP53 mutation ( Xu et al., 2014 ). Furthermore, our evidence of an oncogenic GOF leading to aggressive metastatic tumors in Trp53 Y217C/Y217C male mice is consistent with the oncogenic GOF attributed to p53 Y220C in male patients with glioblastoma ( Rockwell et al., 2021 ) or with experiments suggesting that p53 Y220C expression in p53-null cells, or its overexpression in MCF-10A cells, may increase their migratory or invasive capacities ( Pal et al., 2023 ; Zhou et al., 2022 ). Our transcriptomic analyses suggested that the p53 Y217C mutant might accelerate tumorigenesis by promoting inflammation, a hallmark of cancer ( Hanahan, 2022 ) previously associated with a few other hotspot p53 mutants with oncogenic GOF ( Agupitan et al., 2020 ; Behring et al., 2019 ; Ham et al., 2019 ; Zhao et al., 2024 ). Interestingly, the GSEA comparison of transcriptomes from Trp53 Y217C/Y217C and Trp 53 -/- male thymic cells indicated differences related to inflammation and chemokine signaling, but also to mitochondria function and chromatin plasticity, and a link between inflammation, mitochondrial copper and epigenetic plasticity was recently demonstrated ( Solier et al., 2023 ). Furthermore, the p53 G245D or p53 R273H mutants were proposed to accelerate tumorigenesis by promoting a chromosomal instability that would activate NC-NF-kB signaling and promote tumor cell metastasis ( Zhao et al., 2024 ). Here we observed increased chromosomal instability in Trp53 Y217C/Y217C fibroblasts, increased NC-NF-kB and inflammation-related signaling in Trp53 Y217C/Y217C thymocytes, and increased tumor metastasis in Trp53 Y217C/Y217C mice compared to their Trp53 -/- counterparts. These data suggest that similar mechanisms might underlie the oncogenic properties of the p53 Y217C , p53 G245D and p53 R273H mutants. A striking and unexpected effect of the p53 Y217C mutation was its severe impact on the perinatal viability of female mice, which led to observe only four Trp53 Y217C/Y217C females for 75 Trp53 Y217C/Y217C males at weaning from heterozygous intercrosses, or five Trp53 Y217C/Y217C females for 111 Trp53 Y217C/Y217C males when all weaned animals from relevant crosses were considered. The perinatal lethality of Trp53 Y217C/Y217C females correlated with a high frequency (38.5%) of exencephalic females at E12.5-E16.5 embryonic ages. By comparison, the female to male ratio at weaning was 8/28 for Trp53 -/- mice, and only 0-8% of exencephalic female Trp53 -/- embryos were reported in similar genetic backgrounds ( Armstrong et al., 1995 ; Donehower et al., 1992 ; Sah et al., 1995 ). These observations provide evidence of teratogenic effects for the p53 Y217C mutant protein. Three other mouse p53 models were previously found to cause exencephaly at a higher frequency than a p53 null allele: Trp53 NLS1 , with 3 mutations at residues 316-318 affecting a nuclear localization signal and leading to a predominantly cytoplasmic localization of p53 NLS1 in most cells ( Regeling et al., 2011 ); Trp53 N236S , a mouse model of TP53 N239S , a recurrent but uncommon mutant in human cancers ( Zhao et al., 2019 ); and Bim +/- Trp53 -/- mice, combining p53 loss with an haploinsufficiency in the cytoplasmic proapoptotic regulator Bim/Bcl2l11 ( Delbridge et al., 2019 ). The female-specific lethality of Trp53 N236S mice was proposed to result from increased Xist expression, whereas a decrease in Xist expression was observed in Bim +/- Trp53 -/- mice, suggesting distinct causes for neural tube defects ( Delbridge et al., 2019 ; Zhao et al., 2019 ). We observed decreased Xist expression and an increased expression of X-linked genes in neurospheres from Trp53 Y217C/Y217C females compared to WT females, whereas these genes were expressed at similar levels in neurospheres from Trp53 Y217C/Y217C and Trp53 -/- females. These results are not consistent with the mechanism proposed for exencephaly in the Trp53 N236S mouse model, but might rather reflect a p53 LOF in Trp53 Y217C/Y217C embryos. In addition, the analyses of the Trp53 NLS1 and Bim +/- Trp53 -/- mouse models make it tempting to speculate that, in female Trp53 Y217C/Y217C embryos, the abundance of p53 Y217C in the cytoplasm might perturb mitochondria function ( Blandino et al., 2020 ) to further promote neural tube closure defects. Consistent with this possibility, p53 mutant proteins accumulating in the cytoplasm were reported to inhibit autophagy ( Morselli et al., 2008 ), a key determinant for mitochondrial integrity ( Rambold and Lippincott-Schwartz, 2011 ), and autophagy impairment may promote neural tube defects ( Fimia et al., 2007 ; Ye et al., 2020 ). Importantly, our data suggest that common mechanisms might contribute to the oncogenic effects accelerating tumorigenesis in Trp53 Y217C/Y217C males and the teratogenic effects causing the perinatal lethality of many Trp53 Y217C/Y217C females. Indeed, the RNAseq analysis of male thymocytes indicated that inflammation likely promotes oncogenesis in Trp53 Y217C/Y217C males, and the administration of the anti-inflammatory drug supformin to pregnant mice increased the ratio of Trp53 Y217C/Y217C weaned females in their progeny. Thus, the low female/male ratio observed for Trp53 Y217C/Y217C weaned animals would likely result not only from aberrant X-chromosome inactivation in female embryos as in Trp53 -/- animals ( Delbridge et al., 2019 ), but also from inflammation. Presumably, a higher level of chromosomal instability in Trp53 Y217C/Y217C cells might promote inflammation in Trp53 Y217C/Y217C embryos ( Rodier et al., 2009 ), and this might be more detrimental to females because Trp53 Y217C/Y217C males would be protected by the anti-inflammatory effects of androgens ( Ainslie et al., 2024 ; Bianchi, 2019 ; McNairn et al., 2019 ). Of note, we also observed that decreased Mdm4 levels increased the female/male ratio in Trp53 Y217C/Y217C weaned mice. Because MDM4 overexpression was shown to promote genome instability and inflammation in cells independently of p53 ( Carrillo et al., 2015 ; Liu et al., 2024 ), it is tempting to speculate that, as for supformin-treated mice, the improved survival of Trp53 Y217C/Y217C female embryos in an Mdm4 +/- background might result from decreased inflammation. Interestingly, in the offspring of human pregnancies at risk of early preterm delivery, an Interleukin-6 polymorphism was associated with a female-specific susceptibility to adverse neurodevelopmental outcome ( Varner et al., 2020 ), suggesting that inflammation may also impact the development of human female embryos. Finally, our mating attempts with Trp53 Y217C/Y217C mice indicated that Trp53 Y217C/Y217C pregnant females exhibited dystocia, and parturition is considered to be a finely regulated inflammatory process ( Zhang and Wei, 2021 ). Of note, dystocia was not observed in Trp53 -/- mice, but was previously reported in pregnant females with a combined deficiency of p53 and FasL ( Embree-Ku and Boekelheide, 2002 ). The fact that Trp53 Y217C/Y217C females shared phenotypic traits with both Bim +/- Trp53 -/- mice (neural tube defects) and FasL -/- Trp53 -/- mice (dystocia) may seem relevant, because Bim and FasL are both regulators of apoptosis and autophagy that also regulate immune responses ( Sionov et al., 2015 ; Taylor and Ng, 2018 ). Altogether, these data suggest that inflammation may cause accelerated tumorigenesis in Trp53 Y217C/Y217C male mice and contribute to promote neural tube defects in Trp53 Y217C/Y217C female embryos or dystocia in Trp53 Y217C/Y217C pregnant females ( Table S7 ). In conclusion, we generated a mouse model expressing p53 Y217C , the murine equivalent of human p53 Y220C , and its analysis revealed that the gain-of-function of a hotspot mutant p53 may not be limited to oncogenic effects. This is an important notion to consider given the ever-expanding functions ascribed to p53 ( Hu, 2009 ; Rakotopare and Toledo, 2023 ; Voskarides and Giannopoulou, 2023 ; Vousden and Lane, 2007 ). In addition, our results unveiled the potential relevance of supformin in obstetrics, which deserves further investigation. Materials and Methods LSL-Y217C construct We used mouse genomic Trp53 DNA from previous constructs, containing a portion of intron 1 with a LoxP-Stop-LoxP (LSL) cassette ( Ventura et al., 2007 ) in which the puromycin-resistance gene was replaced by a neomycin-resistance gene ( Simeonova et al., 2013 ). The point mutation (A to G) encoding a Tyr to Cys substitution (TAT to TGT) at codon 217, together with a silent mutation nearby creating a Ban II restriction site, were introduced by PCR directed mutagenesis by using primers Y217C-F and Y217C-R (See Table S8 for primer sequences). The resulting Trp53 LSL-Y217C targeting vector was fully sequenced before use. Targeting in ES Cells and Genotyping 129/SvJ embryonic stem (ES) cells were electroporated with the targeting construct linearized with Not I. Two recombinant clones, identified by long-range PCR and confirmed by internal PCR and Southern Blot, were injected into C57BL/6J blastocysts to generate chimeras, and germline transmission was verified by genotyping their offspring. In vivo excision of the LSL cassette was performed by breeding Trp53 +/LSL-Y217C male mice with females carrying the PGK- Cre transgene ( Lallemand et al., 1998 ) and genotyping their offspring. The Trp53 Y217C (p53 YC ) mutation was routinely genotyped by PCR using primers c and d ( Figure 1 , Table S8 ) followed by BanII digestion. Tumorigenesis studies were performed on mouse cohorts resulting from ≥ 5 generations of backcrosses with C57BL6/J mice. For all experiments, mice housing and treatment were conducted according to the Institutional Animal Care and Use Committee of the Institut Curie (approved project #03769.02). Cells and Cell Culture Reagents Mouse embryonic fibroblasts (MEFs) isolated from 13.5-day embryos were cultured in a 5% CO2 and 3% O2 incubator, in DMEM GlutaMAX (Gibco), with 15% FBS (Biowest), 100 μM 2-mercaptoethanol (Millipore), 0.01 mM Non-Essential Amino-Acids, and penicillin/streptomycin (Gibco) for ≤ 6 passages. Cells were irradiated with a Cs γ-irradiator or treated for 24 hr with 10 μM Nutlin 3a (Sigma-Aldrich) or 1 μM Doxorubicin (Sigma-Aldrich). Neurospheres were prepared by isolating neural stem/progenitor cells (NPCs) from the lateral and median ganglionic eminences of E14.5 embryos. NPCs were cultured in a 5% CO2 incubator, in DMEM/F12 medium (with L-Glutamine, Invitrogen) supplemented with 1% B-27 (Invitrogen), 1% N2 (Invitrogen), 0.3% glucose (Invitrogen), 25 μg/ml insulin (Sigma-Aldrich), 20 ng/ml EGF (PeproTech), 10 ng/ml bFGF (PeproTech) and penicillin/streptomycin (Gibco). Neurospheres were dissociated once a week by Accutase treatment and mechanically, then seeded at 10 6 cells per 6 cm diameter dish. Quantitative RT-PCR Total RNA, extracted using NucleoSpin RNA II (Macherey-Nagel), was reverse transcribed using SuperScript IV (Invitrogen). Real-time quantitative PCRs were performed as previously described ( Simeonova et al., 2012 ), on an ABI PRISM 7500 using Power SYBR Green (Applied Biosystems). Primer sequences are reported in Table S8 . Western Blots Cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 5 mM EDTA, 0.5% deoxycholic acid, 0.1% SDS, 1% NP-40) supplemented with Protease inhibitors cocktail (Roche) and 1 mM PMSF (Sigma). Whole-cell extracts were sonicated three times for 10 s and centrifuged at 13 000 rpm for 30 min to remove cell debris. Protein lysate concentration was determined by BCA assay (Thermo Scientific) and 30 μg of each lysate was fractionated by SDS–PAGE on a 4-12% polyacrylamide gel and transferred onto polyvynilidene difluoride (PVDF) membranes (Amersham). Membranes were incubated with antibodies raised against Mdm2 (MDM2-4B2, Abcam, 1/500), p53 (CM-5, Novocastra, 1/2000), p21 (F5, Santa Cruz Biotechnology, 1/200) and actin (actin-HRP sc47778, Santa Cruz Biotechnology, 1/5000). Chemiluminescence revelation of western blots was achieved with the SuperSignal West Dura (Perbio). ChIP Assay ChIP analysis was performed as previously described ( Simeonova et al., 2013 ). p53-DNA complexes were immunoprecipitated from total extracts by using 50 μg of a polyclonal antibody against p53 (FL-393, Santa Cruz Biotechnology) and 300 μg of sonicated chromatin. Rabbit IgG (Abcam) was used for control precipitation. Quantitative PCR was performed on ABI PRISM 7500. Primer sequences are reported in Table S8 . Cell Fractionation Assay Cells were lysed in hypotonic lysis buffer (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM Mgcl2, 0.3% NP-40, 10% glycerol) on ice for 10 min, then centrifuged at 4°C for 3 min at 1000g. The supernatant was recovered as the cytoplasmic fraction, and the pellet was incubated in a modified Wuarin-Schibler buffer (10 mM Tris-HCl pH 7.0, 4 mM EDTA, 0.3 M NaCl, 1 M urea, 1% NP-40) on ice for 5 min, vortexed, incubated on ice for 10 min, then centrifuged at 4°C for 3 min at 1000g. The supernatant was recovered as the nucleoplasmic fraction, and the pellet was washed, then incubated in a nuclear lysis buffer (20 mM Tris pH 7.5, 150 mM KCl, 3 mM MgCl2, 0.3% NP-40, 10% glycerol) on ice for 5 min, sonicated, then centrifuged at 13000 rpm at 4°C and the supernatant was recovered as the chromatin fraction. All buffers were supplemented with Protease inhibitors cocktail (Roche). Cellular fractions were analyzed by western blots with antibodies against p53 (AF-1355, R&D systems, 1/600), Tubulin (ab15568, Abcam, 1/1000), Nup98 (ab50610, Abcam, 1/1000) and histone H3 (ab1791, Abcam, 1/1000). Chemiluminescence revelation was achieved with SuperSignal West Pico or Femto (Thermoscientific) and analyzed with a ChemiDoc imaging system (Bio-Rad). Immunofluorescence MEFs were cultured on collagen-coated coverslips, treated with 10 μM Nutlin 3a (Sigma-Aldrich) for 24 hr and analyzed. Coverslips were stained with rabbit anti-p53 FL-393 (Santa Cruz Biotechnology, 1/50), mouse anti-actin primary antibody and with Alexa Fluor 647 anti-Rabbit and Alexa Fluor 488 anti-Mouse secondary antibodies (Molecular Probes). DNA was counterstained with DAPI. Images were captured on an epifluorescence microscope using equal exposure times for all images for each fluor. Cell-Cycle Assay Log phase cells were irradiated at room temperature (RT) with a Cs γ-irradiator at doses of 3 or 12 Gy, incubated for 24 hr, then pulse labeled for 1 hr with BrdU (10 μM), fixed in 70% ethanol, double stained with FITC anti-BrdU and propidium iodide, and analyzed by flow cytometry with a BD Biosciences FACSort and the FlowJo software. Apoptosis Assay Six to eight weeks-old mice were left untreated or submitted to 10 Gy whole-body ɣ-irradiation. Mice were sacrificed 4 hr later and thymi were extracted. Thymocytes were recovered by filtration through a 70 μm smash, stained with Annexin V-FITC Apoptosis detection kit (Abcam) and propidium iodide, then analyzed with a LSRII FACS machine. Data were analyzed using Flowjo software. Metaphase spread preparation and analysis Primary MEFs (at passage 4 for all genotypes) were treated with 0.1 mM nocodazole for 3 h to arrest cells in metaphase, then submitted to hypotonic shock (75 mM KCl), fixed in a (3:1) ethanol/acetic acid solution, dropped onto glass slides, then air-dried slides were stained with Giemsa to score for chromosome aberrations. Images were acquired using a Zeiss Axiophot (X63) microscope. Histology Organs were fixed in formol 4% for 24 hr, then ethanol 70%, and embedded in paraffin wax. Serial sections of 3 μm were stained as described ( Simeonova et al., 2013 ), with hematoxylin and eosin using standard procedures. RNA-Seq analysis Total RNA was extracted from the thymi of 8 weeks-old asymptomatic male mice using nucleospin RNA II (Macherey-Nagel). The quality of RNA was checked with Bioanalyzer Agilent 2100 and RNAs with a RIN (RNA integrity number) > 7 were retained for further analysis. RNA was depleted from ribosomal RNA, then converted into cDNA libraries using a TruSeq Stranded Total Library preparation kit (Illumina). Paired-end sequencing was performed on an Illumina MiSeq platform. Reads were mapped to the mouse genome version GRCm38 and counted on gene annotation gencode.vM18 with featureCounts ( Liao et al., 2014 ). Differentially expressed genes with an adjusted p-value < 0.05 were identified using the DESeq2 R package ( Love et al., 2014 ). Gene Ontology analysis Gene ontology analysis of differentially expressed genes was performed by using the GOrilla (Technion) software as previously described ( Rakotopare et al., 2023 ). Enrichment analyses were carried out by comparing the list of 192 differentially expressed genes between Trp53 Y217C/Y217C and Trp53 -/- thymi to the full list of genes (background), with ontology searches for biological processes and default P -value settings (10 −3 ). Gene set enrichment analysis Gene set enrichment analysis was performed by using the GSEA software with canonical pathway gene sets from the Mouse Molecular Signature Database (MSigDB) ( Subramanian et al., 2005 ). Gene sets with a false discovery rate (FDR) q-value < 0.25 were regarded as potentially relevant. The best candidates, with an FDR q-value 1.91 and nominal (NOM) P-values <0.003. Oral gavage of pregnant females Trp53 +/Y217C female mice were mated with Trp53 Y217C/Y217C males, then mice with a vaginal plug on the next day were separated from males and weighted every other day to confirm pregnancy. On the 10 th and 11 th days post-coitum, pregnant mice received 5 mg/kg of supformin (in a PBS solution) by oral gavage with flexible gauge feeding tubes, then their pups were genotyped at weaning. Statistical analyses Unless noted otherwise, we used a Student’s t test to analyze differences between two groups of values. For the proportions of mice at weaning, the observed mouse count was compared to the expected count according to Mendel’s distribution and a Chi-square (χ 2 ) test, and a Fischer’s test was applied to compare frequencies of mutant females or female to male ratios. Fischer’s tests were also used to analyze frequencies of chromosome rearrangements in fibroblasts. Survival curves were analyzed with log-rank Mantel-Cox tests. Analyses were performed by using GraphPad Prism, and values of P ≤ 0.05 were considered significant. Data availability RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) under the accession code GSE248936. All other data are available within the article and its supplementary information. Author Contributions Conceptualization: F.T.; investigation: S.J., E.E., J.R., I.S, V.L., V.V., M.L., A.F., B.B., F.T.; formal analysis: M.G., B.B., F.T.; resources: T.C., R.R., A.M.; supervision, writing and visualization: F.T., B.B; project administration and funding acquisition: F.T. Declaration of interests The authors declare no competing financial interests. Supplemental Figures Download figure Open in new tab Figure S1. Protein sequence alignment showing homology between mouse p53 Tyrosine 217 and human p53 Tyrosine 220. Portions of the DNA binding domains from the mouse (residues 208-228) and human (residues 211-231) p53 proteins are shown, with identical residues in bold, and mouse Tyrosine 217 and human Tyrosine 220 in red. Download figure Open in new tab Figure S2. Uncropped images of the western blot presented in Figure 2A . All images are from the same blot, cut in two below the 35 kDa marker before incubation with the indicated antibodies. Download figure Open in new tab Figure S3. Uncropped images of the fractionation assays presented in Figure 2C . Chemiluminescence and colorimetric scans obtained with a ChemiDoc imaging system (Bio-Rad) were superposed to show the entire membranes, ladder lanes (λ), and chemiluminescence signals from subcellular fractions. Download figure Open in new tab Figure S4. Cell cycle arrest responses of Trp53 +/+ , Trp53 Y217C/Y217C and Trp53 -/- mouse embryonic fibroblasts. Asynchronous MEFs were exposed to 0-12 Gy ɣ-irradiation, then after 24 hr cells were labelled with BrdU for 1 hr and analyzed by FACS. A typical experiment for cells of each genotype and condition is shown, with % cells in G1, S or G2/M mentioned in each panel. Download figure Open in new tab Figure S5. Apoptotic responses of Trp53 +/+ , Trp53 -/- and Trp53 Y217C/Y217C thymocytes. Mice were ɣ-irradiated (or not) and their thymocytes were recovered and analyzed by FACS after annexin V-FITC staining. A typical experiment for cells of each genotype and condition is shown. Numbers indicate % cells either alive (live), early apoptotic (early) or mid to late apoptotic (mid+late). Download figure Open in new tab Figure S6. Comparison of stress responses in WT, Trp53 +/Y217C and Trp53 +/- cells. (A) Transactivation of the classical p53 target genes Cdkn1a/p21 , Mdm2 and Pmaip1 / Noxa in response to Nutlin or Doxorubicin. WT, Trp53 +/Y217C and Trp53 +/- MEFs were treated or not with 10 μM Nutlin 3a (Nut) or 1 μM Doxorubicin (Doxo) for 24 h, then mRNAs were quantified in ≥ 4 independent experiments using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in unstressed WT cells assigned a value of 1. For each condition and gene, a DNE would lead to significant decrease in transactivation in Trp53 +/Y217C MEFs compared to both WT and Trp53 +/- MEFs, a result that was not observed. (B) Cell cycle arrest responses to ɣ-irradiation. Asynchronous cell populations of WT, Trp53 +/Y217C and Trp53 +/- MEFs were analyzed 24 hr after 0, 3 or 12 Gy ɣ-irradiation, in 3 independent experiments. The comparison of cells submitted to identical irradiation doses revealed similar arrest responses in cells of all genotypes. (C) Apoptotic responses to ɣ-irradiation. WT, Trp53 +/Y217C and Trp53 +/- MEFs age-matched mice were left untreated or submitted to 10 Gy whole-body ɣ-irradiation, then sacrificed after 4 hr and their thymocytes were stained with Annexin V-FITC and analyzed by FACS, in 2 independent experiments. The percentage of apoptotic cells was significantly higher in irradiated WT thymocytes compared to irradiated Trp53 +/Y217C or Trp53 +/- cells, whereas Trp53 +/Y217C and Trp53 +/- cells were not significantly different. **P<0.01, *P<0.05, ns: non-significant by Student’s t test. Download figure Open in new tab Figure S7. Evidence of aberrant chromosome X inactivation in Trp53 Y217C/Y217C and Trp53 -/- female embryos. The expression of Xist and 3 X-linked genes ( Maob , Usp9x and Pls3 ) was quantified in neurospheres from 2 Trp53 +/+ , 5 Trp53 Y217C/Y217C and 3 Trp53 -/- female embryos by using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in WT neurospheres assigned a value of 1. *P<0.05, °P=0.09, ns: non-significant by Student’s t tests. Download figure Open in new tab Figure S8. Trp53 +/Y217C and Trp53 +/- mice exhibit similar tumor onset and spectra. No significant difference was observed between heterozygous Trp53 +/- and Trp53 +/Y217C mice, neither in spontaneous tumor onset and survival (A) , nor in tumor spectra (B) ; n=cohort size. Mice of both sexes were included in this study. Download figure Open in new tab Figure S9. Example of a Trp53 Y217C/Y217C mouse with a thymic lymphoma and lymphomatous infiltrates in the liver and kidney. H&E staining of sections from the thymus (top), liver (middle) and kidney (bottom) of a Trp53 Y217C/Y217C male mouse, showing tumor lymphocytes (TL) in the thymus and lymphocyte infiltrates (LI) in the liver and kidney, near blood vessels (BV). Hepatocytes (H), kidney tubules (TB) and a glomerulus (G) are also indicated. Download figure Open in new tab Figure S10. RNA-seq analysis from the thymi of 8 weeks-old Trp53 +/+ , Trp53 Y217C/Y217C and Trp53 -/- male mice. (A) Heat-Map plot, with 717 differentially expressed genes suggestive of a loss of function (LOF), a separation of function (SOF) or a gain of function (GOF) for the p53 Y217C mutant, ranked according to log 2 fold change (n=number of genes). (B) Evidence of LOF in Trp53 Y217C/Y217C cells for genes encoding Puma, p21 and Zmat3. Data from 3 mice per genotype. ***P<0.001, **P<0.01, *P<0.05, °P=0.07, ns: non-significant by Student’s t tests. Download figure Open in new tab Figure S11. Gene ontology analysis of differentially expressed genes. The 192 differentially expressed genes (DEGs) between Trp53 -/- and Trp53 Y217C/Y217C thymocytes ( Fig. 5A ) were analyzed with the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla). Out of 192 genes, 141 were associated with a GO term. For each GO term, enrichment was calculated by comparing with the full list of 19759 genes associated with a GO term. For example, genes with GO term #0071621 (granulocyte chemotaxis) represent 79/19759 genes associated with a GO term, but 8/141 of the identified DEGs, which represents a 14.19-fold enrichment. Download figure Open in new tab Figure S12. Gene set enrichment analysis (GSEA) of transcriptomes from Trp53 Y217C/Y217C (Y220C) and Trp53 -/- (KO) thymic cells: examples of GSEA enrichment plots. Examples of GSEA enrichment plots indicating differences in immune responses (A) , mitochondrial function (B) and chromatin plasticity (C) are shown. Download figure Open in new tab Figure S13. GSEA enrichment plot showing increased NC-NF-kB signaling in Trp53 Y217C/Y217C cells. Transcriptomes from Trp53 Y217C/Y217C (Y220C) and Trp53 -/- (KO) thymic cells were compared by Gene Set Enrichment Analysis. Supplementary Tables View this table: View inline View popup Download powerpoint Table S1. Viability of Mdm2 or Mdm4 loss in a Trp53 Y217C/Y217C background. Mouse distributions from the indicated crosses were determined at weaning. As for Trp53 +/Y217C intercrosses, these crosses yielded a deficit in weaned Trp53 Y217C/Y217C females compared to Trp53 Y217C/Y217C males (4/75 from Trp53 +/Y217C intercrosses ( Figure 3A ); 0/9 from crosses between Mdm4 +/- Trp53 +/Y217C and Mdm4 +/- Trp53 Y217C/Y217C mice; and 0/5 from mating Mdm2 +/- Trp53 +/Y217C mice with Mdm2 +/- Trp53 Y217C/Y217C or Mdm2 -/- Trp53 Y217C/Y217C animals). Trp53 Y217C/Y217C females over Mdm4 or Mdm2 deficient or haplo-insufficient backgrounds were also less frequent than their male counterparts, but the female/male ratio for Trp53 Y217C/Y217C mice over a Mdm4 +/- background (4/15) was significantly increased (P=0.04 when 4/75 and 4/15 ratios are compared in a Fischer’s test). Whether or not the female/male ratios for Trp53 Y217C/Y217C mice were significantly increased over Mdm4 -/- (1/6), Mdm2 -/- (1/11) or Mdm2 +/- (1/11) backgrounds remained uncertain due to limited animal numbers. View this table: View inline View popup Download powerpoint Table S2. Evidence of dystocia in pregnant Trp53 Y217C/Y217C females. Results of the mating of two (a and b) Trp53 Y217C/Y217C females (F) with a Trp53 +/Y217C male (M) are shown. Both females were rapidly pregnant after encountering a male, but had to be sacrificed due to extended labor and pain during their first (female a) or third (female b) delivery. View this table: View inline View popup Table S3. Differentially expressed genes between WT, Trp53 Y217C/Y217C (YC) and Trp53 -/- (KO) thymocytes from age-matched animals. Most differentially expressed genes correspond to a loss of function (LOF) in the p53 Y217C mutant (categories 1 and 2, see Figure S10A ), but genes corresponding to a separation of function (SOF, categories 3 and 4) or a gain of function (GOF, categories 5 and 6) were also observed. View this table: View inline View popup Download powerpoint Table S4. A De-Seq analysis of RNA seq data from Trp53 -/- (KO) and Trp53 Y217C/Y217C (YC) thymi revealed 192 differentially expressed genes. As shown in Figure 5B , 107 genes (in bold) were less expressed and 85 genes were more expressed in Trp53 Y217C/Y217C cells compared to Trp53 -/- cells. View this table: View inline View popup Download powerpoint Table S5. Ccl17 , Ccl9 , Ccr3 , Cxcl10 , S100a8 and S100a9 are associated with GO terms of white blood cell migration/chemotaxis and inflammation. View this table: View inline View popup Download powerpoint Table S6. Distribution of weaned pups after mating Trp53 +/Y217C females with Trp53 Y217C/Y217C males and oral gavage of pregnant females with supformin. Due to the gavage of pregnant mothers, all the pups born in this experiment were exposed to supformin in utero (SIU+). View this table: View inline View popup Download powerpoint Table S7. Effects of the Trp53 Y217C mutation: a summary. The comparison between Trp53 -/- and Trp53 Y217C/Y217C mice is presented. The phenotypes observed in Trp53 -/- male (M) and female (F) mice result from p53 loss of function (LOF), whereas those observed in Trp53 Y217C/Y217C mice result from p53 LOF as well as additional effects (gain of function (GOF) in red). The + signs denote the presence of a phenotype. Xi: X chromosome inactivation. View this table: View inline View popup Download powerpoint Table S8. Primers used in this study. Acknowledgments This project was supported by grants attributed to F.T., from the Ligue Nationale Contre le Cancer, the Fondation ARC pour la recherche sur le Cancer and the Gefluc. S.J., E.E. and J.R. were PhD fellows of the Ministère de la Recherche, supervised by F.T. (S.J., J.R.) or B.B. (E.E.). S.J. and E.E. received additional support from the Fondation ARC. M.G. was paid by European Research Council 875532-Prostator-ERC-2019-PoC attributed to A.M. For some experiments, S.J. and V.V. received technical assistance from C. Bouyer and R. Bourimi. We thank the following members of the Institut Curie platforms: I. Grandjean, H. Gautier, C. Daviaud, M. Garcia, D. Andreau, M. Verlhac and A. Fosse (animal facility); S. Baulande and S. Lameiras (NGS); M. Huerre, A. Nicolas and R. Leclere (histopathology); Z. Maciorowski, A. Viguier and S. Grondin (flow cytometry). Footnotes New results in Fig. 2G, 5F, 5G, S6, S9, S13 and Table S6. Updated data in Fig. 3A and Table S1. Title, abstract, results and discussion have been modified accordingly. References ↵ Agupitan AD , Neeson P , Williams S , Howitt J , Haupt S , Haupt Y . 2020 . P53: A Guardian of Immunity Becomes Its Saboteur through Mutation . Int J Mol Sci 21 : 3452 . doi: 10.3390/ijms21103452 OpenUrl CrossRef PubMed ↵ Ainslie RJ , Simitsidellis I , Kirkwood PM , Gibson DA . 2024 . RISING STARS: Androgens and immune cell function . J Endocrinol 261 : e230398 . doi: 10.1530/JOE-23-0398 OpenUrl CrossRef PubMed ↵ Amelio I , Melino G . 2020 . Context is everything: extrinsic signalling and gain-of-function p53 mutants . Cell Death Discov 6 : 16 . doi: 10.1038/s41420-020-0251-x OpenUrl CrossRef PubMed ↵ Armstrong JF , Kaufman MH , Harrison DJ , Clarke AR . 1995 . High-frequency developmental abnormalities in p53-deficient mice . Curr Biol 5 : 931 – 936 . doi: 10.1016/s0960-9822(95)00183-7 OpenUrl CrossRef PubMed Web of Science ↵ Aubrey BJ , Janic A , Chen Y , Chang C , Lieschke EC , Diepstraten ST , Kueh AJ , Bernardini JP , Dewson G , O’Reilly LA , Whitehead L , Voss AK , Smyth GK , Strasser A , Kelly GL . 2018 . Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development . Genes Dev 32 : 1420 – 1429 . doi: 10.1101/gad.314286.118 OpenUrl Abstract / FREE Full Text ↵ Bardot B , Bouarich-Bourimi R , Leemput J , Lejour V , Hamon A , Plancke L , Jochemsen AG , Simeonova I , Fang M , Toledo F . 2015 . Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity . Oncogene 34 : 2943 – 2948 . doi: 10.1038/onc.2014.230 OpenUrl CrossRef PubMed ↵ Beckerman R , Prives C . 2010 . Transcriptional regulation by p53 . Cold Spring Harb Perspect Biol 2 : a000935 . doi: 10.1101/cshperspect.a000935 OpenUrl Abstract / FREE Full Text ↵ Behring M , Vazquez AI , Cui X , Irvin MR , Ojesina AI , Agarwal S , Manne U , Shrestha S . 2019 . Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages . Molec Genet Genomic Med 7 : e1001 . doi: 10.1002/mgg3.1001 OpenUrl CrossRef ↵ Bianchi VE . 2019 . The Anti-Inflammatory Effects of Testosterone . J Endocr Soc 3 : 91 – 107 . doi: 10.1210/js.2018-00186 OpenUrl CrossRef PubMed ↵ Blandino G , Valenti F , Sacconi A , Di Agostino S. 2020 . Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease . Semin Cell Dev Biol 98 : 105 – 117 . doi: 10.1016/j.semcdb.2019.05.011 OpenUrl CrossRef PubMed ↵ Boettcher S , Miller PG , Sharma R , McConkey M , Leventhal M , Krivtsov AV , Giacomelli AO , Wong W , Kim J , Chao S , Kurppa KJ , Yang X , Milenkowic K , Piccioni F , Root DE , Rücker FG , Flamand Y , Neuberg D , Lindsley RC , Jänne PA , Hahn WC , Jacks T , Döhner H , Armstrong SA , Ebert BL . 2019 . A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies . Science 365 : 599 – 604 . doi: 10.1126/science.aax3649 OpenUrl Abstract / FREE Full Text ↵ Bouaoun L , Sonkin D , Ardin M , Hollstein M , Byrnes G , Zavadil J , Olivier M . 2016 . TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data . Hum Mutat 37 : 865 – 876 . doi: 10.1002/humu.23035 OpenUrl CrossRef PubMed ↵ Brennan MS , Brinkmann K , Romero Sola G , Healey G , Gibson L , Gangoda L , Potts MA , Lieschke E , Wilcox S , Strasser A , Herold MJ , Janic A . 2023 . Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice . Cell Death Differ . doi: 10.1038/s41418-023-01250-w OpenUrl CrossRef ↵ Carrillo AM , Bouska A , Arrate MP , Eischen CM . 2015 . Mdmx promotes genomic instability independent of p53 and Mdm2 . Oncogene 34 : 846 – 856 . doi: 10.1038/onc.2014.27 OpenUrl CrossRef PubMed ↵ Delbridge ARD , Kueh AJ , Ke F , Zamudio NM , El-Saafin F , Jansz N , Wang G-Y , Iminitoff M , Beck T , Haupt S , Hu Y , May RE , Whitehead L , Tai L , Chiang W , Herold MJ , Haupt Y , Smyth GK , Thomas T , Blewitt ME , Strasser A , Voss AK . 2019 . Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube Defects . Cell Rep 27 : 442 – 454 .e5. doi: 10.1016/j.celrep.2019.03.048 OpenUrl CrossRef ↵ Dibra D , Xiong S , Moyer SM , El-Naggar AK , Qi Y , Su X , Kong EK , Korkut A , Lozano G . 2024 . Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo . Sci Adv 10 : eadk1835 . doi: 10.1126/sciadv.adk1835 OpenUrl CrossRef PubMed ↵ Dittmer D , Pati S , Zambetti G , Chu S , Teresky AK , Moore M , Finlay C , Levine AJ . 1993 . Gain of function mutations in p53 . Nat Genet 4 : 42 – 46 . doi: 10.1038/ng0593-42 OpenUrl CrossRef PubMed Web of Science ↵ Donehower LA , Harvey M , Slagle BL , McArthur MJ , Montgomery CA , Butel JS , Bradley A . 1992 . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours . Nature 356 : 215 – 221 . doi: 10.1038/356215a0 OpenUrl CrossRef PubMed Web of Science ↵ Dumbrava E , Johnson M , Tolcher A , Shapiro G , Thompson J , El-Khoueiry A , Vandross A , Kummar S , Parikh A , Munster P , Daly E , De Leon L , Khaddar M , LeDuke K , Robell K , Sheehan L , St. Louis M , Wiebesiek A , Alland L , Schram A. 2022 . First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation . J Clin Oncol 40 : suppl 3003 . doi: 10.1200/JCO.2022.40.16_suppl.3003 OpenUrl CrossRef ↵ Eden E , Navon R , Steinfeld I , Lipson D , Yakhini Z . 2009 . GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists . BMC Bioinformatics 10 : 48 . doi: 10.1186/1471-2105-10-48 OpenUrl CrossRef PubMed ↵ Embree-Ku M , Boekelheide K . 2002 . Absence of p53 and FasL has sexually dimorphic effects on both development and reproduction . Exp Biol Med (Maywood) 227 : 545 – 553 . doi: 10.1177/153537020222700720 OpenUrl CrossRef PubMed ↵ Feinberg AP , Ohlsson R , Henikoff S . 2006 . The epigenetic progenitor origin of human cancer . Nat Rev Genet 7 : 21 – 33 . doi: 10.1038/nrg1748 OpenUrl CrossRef PubMed Web of Science ↵ Fimia GM , Stoykova A , Romagnoli A , Giunta L , Di Bartolomeo S , Nardacci R , Corazzari M , Fuoco C , Ucar A , Schwartz P , Gruss P , Piacentini M , Chowdhury K , Cecconi F. 2007 . Ambra1 regulates autophagy and development of the nervous system . Nature 447 : 1121 – 1125 . doi: 10.1038/nature05925 OpenUrl CrossRef PubMed Web of Science ↵ Finch RA , Donoviel DB , Potter D , Shi M , Fan A , Freed DD , Wang C-Y , Zambrowicz BP , Ramirez-Solis R , Sands AT , Zhang N . 2002 . mdmx is a negative regulator of p53 activity in vivo . Cancer Res 62 : 3221 – 3225 . OpenUrl Abstract / FREE Full Text ↵ Funk JS , Klimovich M , Drangenstein D , Pielhoop O , Hunold P , Borowek A , Noeparast M , Pavlakis E , Neumann M , Balourdas D-I , Kochhan K , Merle N , Bullwinkel I , Wanzel M , Elmshäuser S , Teply-Szymanski J , Nist A , Procida T , Bartkuhn M , Humpert K , Mernberger M , Savai R , Soussi T , Joerger AC , Stiewe T . 2025 . Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations . Nat Genet 57 : 140 – 153 . doi: 10.1038/s41588-024-02039-4 OpenUrl CrossRef PubMed ↵ Gencel-Augusto J , Lozano G . 2020 . p53 tetramerization: at the center of the dominant-negative effect of mutant p53 . Genes Dev 34 : 1128 – 1146 . doi: 10.1101/gad.340976.120 OpenUrl Abstract / FREE Full Text ↵ Gener-Ricos G , Bewersdorf JP , Loghavi S , Bataller A , Goldberg AD , Sasaki K , Famulare C , Takahashi K , Issa GC , Borthakur G , Kadia TM , Short NJ , Senapati J , Carter BZ , Patel KP , Kantarjian H , Andreeff M , Stein EM , DiNardo CD . 2024 . TP53 Y220C mutations in patients with myeloid malignancies . Leukemia & Lymphoma 65 : 1511 – 1515 . doi: 10.1080/10428194.2024.2363440 OpenUrl CrossRef PubMed ↵ Greten FR , Grivennikov SI . 2019 . Inflammation and Cancer: Triggers, Mechanisms, and Consequences . Immunity 51 : 27 – 41 . doi: 10.1016/j.immuni.2019.06.025 OpenUrl CrossRef PubMed ↵ Guimond MJ , Wang B , Fujita J , Terhorst C , Croy BA . 1996 . Pregnancy-associated uterine granulated metrial gland cells in mutant and transgenic mice . Am J Reprod Immunol 35 : 501 – 509 . doi: 10.1111/j.1600-0897.1996.tb00049.x OpenUrl CrossRef PubMed ↵ Hainaut P , Pfeifer GP . 2016 . Somatic TP53 Mutations in the Era of Genome Sequencing . Cold Spring Harb Perspect Med 6 : a026179 . doi: 10.1101/cshperspect.a026179 OpenUrl Abstract / FREE Full Text ↵ Ham SW , Jeon H-Y , Jin X , Kim E-J , Kim J-K , Shin YJ , Lee Y , Kim SH , Lee SY , Seo S , Park MG , Kim H-M , Nam D-H , Kim H . 2019 . TP53 gain-of-function mutation promotes inflammation in glioblastoma . Cell Death Differ 26 : 409 – 425 . doi: 10.1038/s41418-018-0126-3 OpenUrl CrossRef PubMed ↵ Hanahan D . 2022 . Hallmarks of Cancer: New Dimensions . Cancer Discovery 12 : 31 – 46 . doi: 10.1158/2159-8290.CD-21-1059 OpenUrl Abstract / FREE Full Text ↵ Hanel W , Marchenko N , Xu S , Yu SX , Weng W , Moll U . 2013 . Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis . Cell Death Differ 20 : 898 – 909 . doi: 10.1038/cdd.2013.17 OpenUrl CrossRef PubMed Web of Science ↵ Hollstein M , Sidransky D , Vogelstein B , Harris CC . 1991 . p53 mutations in human cancers . Science 253 : 49 – 53 . doi: 10.1126/science.1905840 OpenUrl Abstract / FREE Full Text ↵ Hu W . 2009 . The role of p53 gene family in reproduction . Cold Spring Harb Perspect Biol 1 : a001073 . doi: 10.1101/cshperspect.a001073 OpenUrl Abstract / FREE Full Text ↵ Hu W , Feng Z , Teresky AK , Levine AJ . 2007 . p53 regulates maternal reproduction through LIF . Nature 450 : 721 – 724 . doi: 10.1038/nature05993 OpenUrl CrossRef PubMed Web of Science ↵ Humpton TJ , Hock AK , Maddocks ODK , Vousden KH . 2018 . p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant . Cancer Metab 6 : 18 . doi: 10.1186/s40170-018-0191-6 OpenUrl CrossRef PubMed ↵ Iwakuma T , Parant JM , Fasulo M , Zwart E , Jacks T , de Vries A , Lozano G. 2004 . Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice . Oncogene 23 : 7644 – 7650 . doi: 10.1038/sj.onc.1207793 OpenUrl CrossRef PubMed Web of Science ↵ Jacks T , Remington L , Williams BO , Schmitt EM , Halachmi S , Bronson RT , Weinberg RA . 1994 . Tumor spectrum analysis in p53-mutant mice . Curr Biol 4 : 1 – 7 . doi: 10.1016/s0960-9822(00)00002-6 OpenUrl CrossRef PubMed Web of Science ↵ Joerger AC , Ang HC , Fersht AR . 2006 . Structural basis for understanding oncogenic p53 mutations and designing rescue drugs . Proc Natl Acad Sci U S A 103 : 15056 – 15061 . doi: 10.1073/pnas.0607286103 OpenUrl Abstract / FREE Full Text ↵ Jones SN , Roe AE , Donehower LA , Bradley A . 1995 . Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 . Nature 378 : 206 – 208 . doi: 10.1038/378206a0 OpenUrl CrossRef PubMed Web of Science ↵ Kadosh E , Snir-Alkalay I , Venkatachalam A , May S , Lasry A , Elyada E , Zinger A , Shaham M , Vaalani G , Mernberger M , Stiewe T , Pikarsky E , Oren M , Ben-Neriah Y . 2020 . The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic . Nature 586 : 133 – 138 . doi: 10.1038/s41586-020-2541-0 OpenUrl CrossRef PubMed ↵ Karthik KV , Rajalingam A , Shivashankar M , Ganjiwale A . 2022 . Recursive Feature Elimination-based Biomarker Identification for Open Neural Tube Defects . Curr Genomics 23 : 195 – 206 . doi: 10.2174/1389202923666220511162038 OpenUrl CrossRef PubMed ↵ Kastan MB , Zhan Q , el-Deiry WS , Carrier F , Jacks T , Walsh WV , Plunkett BS , Vogelstein B , Fornace AJ. 1992 . A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia . Cell 71 : 587 – 597 . doi: 10.1016/0092-8674(92)90593-2 OpenUrl CrossRef PubMed Web of Science ↵ Kennedy MC , Lowe SW . 2022 . Mutant p53: it’s not all one and the same . Cell Death Differ 29 : 983 – 987 . doi: 10.1038/s41418-022-00989-y OpenUrl CrossRef ↵ Kim E , Deppert W . 2007 . Interactions of mutant p53 with DNA: guilt by association . Oncogene 26 : 2185 – 2190 . doi: 10.1038/sj.onc.1210312 OpenUrl CrossRef PubMed Web of Science ↵ Kim MP , Lozano G . 2018 . Mutant p53 partners in crime . Cell Death Differ 25 : 161 – 168 . doi: 10.1038/cdd.2017.185 OpenUrl CrossRef PubMed ↵ Kotler E , Shani O , Goldfeld G , Lotan-Pompan M , Tarcic O , Gershoni A , Hopf TA , Marks DS , Oren M , Segal E . 2018 . A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation . Mol Cell 71 : 178 – 190 .e8. doi: 10.1016/j.molcel.2018.06.012 OpenUrl CrossRef PubMed ↵ Kroemer G , Pouyssegur J . 2008 . Tumor Cell Metabolism: Cancer’s Achilles’ Heel . Cancer Cell 13 : 472 – 482 . doi: 10.1016/j.ccr.2008.05.005 OpenUrl CrossRef PubMed Web of Science ↵ Lallemand Y , Luria V , Haffner-Krausz R , Lonai P . 1998 . Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinase . Transgenic Res 7 : 105 – 112 . doi: 10.1023/a:1008868325009 OpenUrl CrossRef PubMed Web of Science ↵ Lian Q , Dheen ST , Liao D , Tay SSW . 2004 . Enhanced inflammatory response in neural tubes of embryos derived from diabetic mice exposed to a teratogen . J of Neuroscience Research 75 : 554 – 564 . doi: 10.1002/jnr.20006 OpenUrl CrossRef PubMed Web of Science ↵ Liao Y , Smyth GK , Shi W . 2014 . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features . Bioinformatics 30 : 923 – 930 . doi: 10.1093/bioinformatics/btt656 OpenUrl CrossRef PubMed Web of Science ↵ Liu J , Yang J , Pan Q , Wang Xiangyu , Wang Xinyin , Chen H , Zheng X , Huang Q . 2024 . MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers . Eur J Med Res 29 : 79 . doi: 10.1186/s40001-024-01684-z OpenUrl CrossRef PubMed ↵ Love MI , Huber W , Anders S . 2014 . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 . Genome Biol 15 : 550 . doi: 10.1186/s13059-014-0550-8 OpenUrl CrossRef PubMed ↵ Lowe SW , Schmitt EM , Smith SW , Osborne BA , Jacks T . 1993 . p53 is required for radiation-induced apoptosis in mouse thymocytes . Nature 362 : 847 – 849 . doi: 10.1038/362847a0 OpenUrl CrossRef PubMed Web of Science ↵ Marine J-C , Francoz S , Maetens M , Wahl G , Toledo F , Lozano G . 2006 . Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 . Cell Death Differ 13 : 927 – 934 . doi: 10.1038/sj.cdd.4401912 OpenUrl CrossRef PubMed Web of Science ↵ McCann JJ , Vasilevskaya IA , McNair C , Gallagher P , Neupane NP , De Leeuw R , Shafi AA , Dylgjeri E , Mandigo AC , Schiewer MJ , Knudsen KE. 2022 . Mutant p53 elicits context-dependent pro-tumorigenic phenotypes . Oncogene 41 : 444 – 458 . doi: 10.1038/s41388-021-01903-5 OpenUrl CrossRef PubMed ↵ McNairn AJ , Chuang C-H , Bloom JC , Wallace MD , Schimenti JC . 2019 . Female-biased embryonic death from inflammation induced by genomic instability . Nature 567 : 105 – 108 . doi: 10.1038/s41586-019-0936-6 OpenUrl CrossRef PubMed ↵ Migliorini D , Lazzerini Denchi E , Danovi D , Jochemsen A , Capillo M , Gobbi A , Helin K , Pelicci PG , Marine J-C . 2002 . Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development . Mol Cell Biol 22 : 5527 – 5538 . doi: 10.1128/MCB.22.15.5527-5538.2002 OpenUrl Abstract / FREE Full Text ↵ Montes de Oca Luna R , Wagner DS , Lozano G . 1995 . Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 . Nature 378 : 203 – 206 . doi: 10.1038/378203a0 OpenUrl CrossRef PubMed Web of Science ↵ Morselli E , Tasdemir E , Maiuri MC , Galluzzi L , Kepp O , Criollo A , Vicencio JM , Soussi T , Kroemer G . 2008 . Mutant p53 protein localized in the cytoplasm inhibits autophagy . Cell Cycle 7 : 3056 – 3061 . doi: 10.4161/cc.7.19.6751 OpenUrl CrossRef PubMed Web of Science ↵ Pal A , Gonzalez-Malerva L , Eaton S , Xu C , Zhang Y , Grief D , Sakala L , Nwekwo L , Zeng J , Christensen G , Gupta C , Streitwieser E , Singharoy A , Park JG , LaBaer J . 2023 . Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants . NPJ Breast Cancer 9 : 78 . doi: 10.1038/s41523-023-00582-7 OpenUrl CrossRef PubMed ↵ Parant J , Chavez-Reyes A , Little NA , Yan W , Reinke V , Jochemsen AG , Lozano G . 2001 . Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 . Nat Genet 29 : 92 – 95 . doi: 10.1038/ng714 OpenUrl CrossRef PubMed Web of Science ↵ Pfister NT , Prives C . 2017 . Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53 . Cold Spring Harb Perspect Med 7 : a026054 . doi: 10.1101/cshperspect.a026054 OpenUrl Abstract / FREE Full Text ↵ Rakotopare J , Lejour V , Duval C , Eldawra E , Escoffier H , Toledo F . 2023 . A systematic approach identifies p53-DREAM pathway target genes associated with blood or brain abnormalities . Dis Model Mech 16 : dmm050376 . doi: 10.1242/dmm.050376 OpenUrl CrossRef ↵ Rakotopare J , Toledo F . 2023 . p53 in the Molecular Circuitry of Bone Marrow Failure Syndromes . Int J Mol Sci 24 : 14940 . doi: 10.3390/ijms241914940 OpenUrl CrossRef ↵ Rambold AS , Lippincott-Schwartz J . 2011 . Mechanisms of mitochondria and autophagy crosstalk . Cell Cycle 10 : 4032 – 4038 . doi: 10.4161/cc.10.23.18384 OpenUrl CrossRef PubMed Web of Science ↵ Regeling A , Armata HL , Gallant J , Jones SN , Sluss HK . 2011 . Mice defective in p53 nuclear localization signal 1 exhibit exencephaly . Transgenic Res 20 : 899 – 912 . doi: 10.1007/s11248-010-9468-4 OpenUrl CrossRef PubMed ↵ Rockwell NC , Yang W , Warrington NM , Staller MV , Griffith M , Griffith OL , Gurnett CA , Cohen BA , Baldridge D , Rubin JB . 2021 . Sex- and Mutation-Specific p53 Gain-of-Function Activity in Gliomagenesis . Cancer Research Communications 1 : 148 – 163 . doi: 10.1158/2767-9764.CRC-21-0026 OpenUrl CrossRef PubMed ↵ Rodier F , Coppé J-P , Patil CK , Hoeijmakers WAM , Muñoz DP , Raza SR , Freund A , Campeau E , Davalos AR , Campisi J . 2009 . Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion . Nat Cell Biol 11 : 973 – 979 . doi: 10.1038/ncb1909 OpenUrl CrossRef PubMed Web of Science ↵ Sah VP , Attardi LD , Mulligan GJ , Williams BO , Bronson RT , Jacks T . 1995 . A subset of p53-deficient embryos exhibit exencephaly . Nat Genet 10 : 175 – 180 . doi: 10.1038/ng0695-175 OpenUrl CrossRef PubMed Web of Science ↵ Shirole N , Pal D , Kastenhuber E , Senturk S , Boroda J , Pisterzi P , Miller M , Munoz G , Anderluh M , Ladanyi M , Lowe S , Sordella R . 2016 . TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions . Elife e17929 . doi : doi: 10.7554/eLife.17929 OpenUrl CrossRef ↵ Simeonova I , Jaber S , Draskovic I , Bardot B , Fang M , Bouarich-Bourimi R , Lejour V , Charbonnier L , Soudais C , Bourdon J-C , Huerre M , Londono-Vallejo A , Toledo F . 2013 . Mutant mice lacking the p53 C-terminal domain model telomere syndromes . Cell Rep 3 : 2046 – 2058 . doi: 10.1016/j.celrep.2013.05.028 OpenUrl CrossRef PubMed ↵ Simeonova I , Lejour V , Bardot B , Bouarich-Bourimi R , Morin A , Fang M , Charbonnier L , Toledo F . 2012 . Fuzzy Tandem Repeats Containing p53 Response Elements May Define Species-Specific p53 Target Genes . PLoS Genet 8 : e1002731 . doi: 10.1371/journal.pgen.1002731 OpenUrl CrossRef PubMed ↵ Sionov RV , Vlahopoulos SA , Granot Z . 2015 . Regulation of Bim in Health and Disease . Oncotarget 6 : 23058 – 23134 . doi: 10.18632/oncotarget.5492 OpenUrl CrossRef PubMed ↵ Solier S , Müller S , Cañeque T , Versini A , Mansart A , Sindikubwabo F , Baron L , Emam L , Gestraud P , Pantoș GD , Gandon V , Gaillet C , Wu T-D , Dingli F , Loew D , Baulande S , Durand S , Sencio V , Robil C , Trottein F , Péricat D , Näser E , Cougoule C , Meunier E , Bègue A-L , Salmon H , Manel N , Puisieux A , Watson S , Dawson MA , Servant N , Kroemer G , Annane D , Rodriguez R. 2023 . A druggable copper-signalling pathway that drives inflammation . Nature 617 : 386 – 394 . doi: 10.1038/s41586-023-06017-4 OpenUrl CrossRef PubMed ↵ Stein Y , Aloni-Grinstein R , Rotter V . 2020 . Mutant p53 oncogenicity: dominant-negative or gain-of-function? Carcinogenesis 41 : 1635 – 1647 . doi: 10.1093/carcin/bgaa117 OpenUrl CrossRef PubMed ↵ Subramanian A , Tamayo P , Mootha VK , Mukherjee S , Ebert BL , Gillette MA , Paulovich A , Pomeroy SL , Golub TR , Lander ES , Mesirov JP . 2005 . Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles . Proc Natl Acad Sci USA 102 : 15545 – 15550 . doi: 10.1073/pnas.0506580102 OpenUrl Abstract / FREE Full Text ↵ Tateossian H , Morse S , Simon MM , Dean CH , Brown SDM . 2015 . Interactions between the otitis media gene, Fbxo11, and p53 in the mouse embryonic lung . Disease Models & Mechanisms dmm.022426 . doi: 10.1242/dmm.022426 OpenUrl Abstract / FREE Full Text ↵ Taylor AW , Ng TF . 2018 . Negative regulators that mediate ocular immune privilege . J Leukoc Biol . doi: 10.1002/JLB.3MIR0817-337R OpenUrl CrossRef ↵ Toledo F , Krummel KA , Lee CJ , Liu C-W , Rodewald L-W , Tang M , Wahl GM . 2006 . A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network . Cancer Cell 9 : 273 – 285 . doi: 10.1016/j.ccr.2006.03.014 OpenUrl CrossRef PubMed Web of Science ↵ Tseng T-H , Wang C-J , Lee Y-J , Shao Y-C , Shen C-H , Lee K-C , Tung S-Y , Kuo H-C . 2022 . Suppression of the Proliferation of Huh7 Hepatoma Cells Involving the Downregulation of Mutant p53 Protein and Inactivation of the STAT 3 Pathway with Ailanthoidol . Int J Mol Sci 23 : 5102 . doi: 10.3390/ijms23095102 OpenUrl CrossRef PubMed ↵ Varner MW , Costantine MM , Jablonski KA , Rouse DJ , Mercer BM , Leveno KJ , Reddy UM , Buhimschi C , Wapner RJ , Sorokin Y , Thorp JM , Ramin SM , Malone FD , Carpenter M , O’sullivan MJ , Peaceman AM , Dudley DJ , Caritis SN , Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network . 2020 . Sex-Specific Genetic Susceptibility to Adverse Neurodevelopmental Outcome in Offspring of Pregnancies at Risk of Early Preterm Delivery . Am J Perinatol 37 : 281 – 290 . doi: 10.1055/s-0039-1678535 OpenUrl CrossRef PubMed ↵ Vassilev LT , Vu BT , Graves B , Carvajal D , Podlaski F , Filipovic Z , Kong N , Kammlott U , Lukacs C , Klein C , Fotouhi N , Liu EA . 2004 . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 . Science 303 : 844 – 848 . doi: 10.1126/science.1092472 OpenUrl Abstract / FREE Full Text ↵ Ventura A , Kirsch DG , McLaughlin ME , Tuveson DA , Grimm J , Lintault L , Newman J , Reczek EE , Weissleder R , Jacks T . 2007 . Restoration of p53 function leads to tumour regression in vivo . Nature 445 : 661 – 665 . doi: 10.1038/nature05541 OpenUrl CrossRef PubMed Web of Science ↵ Vikhanskaya F , Lee MK , Mazzoletti M , Broggini M , Sabapathy K . 2007 . Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53 . Nucleic Acids Res 35 : 2093 – 2104 . doi: 10.1093/nar/gkm099 OpenUrl CrossRef PubMed Web of Science ↵ Voskarides K , Giannopoulou N . 2023 . The Role of TP53 in Adaptation and Evolution . Cells 12 : 512 . doi: 10.3390/cells12030512 OpenUrl CrossRef ↵ Vousden KH , Lane DP . 2007 . p53 in health and disease . Nat Rev Mol Cell Biol 8 : 275 – 283 . doi: 10.1038/nrm2147 OpenUrl CrossRef PubMed Web of Science ↵ Wang Z , Burigotto M , Ghetti S , Vaillant F , Tan T , Capaldo B , Palmieri M , Hirokawa Y , Tai L , Simpson D , Chang C , Huang A , Lieschke E , Diepstraten S , Kaloni D , Riffkin C , Huang D , Li Wai Suen C , Garnham A , Gibbs P , Visvader J , Sieber O , Herold M , Fava L , Kelly G , Strasser A . 2023 . Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival and metastasis of a broad range of cancer cells . Cancer Discov . doi: 10.1158/2159-8290.CD-23-0402 . OpenUrl CrossRef ↵ Xiong S , Chachad D , Zhang Y , Gencel-Augusto J , Sirito M , Pant V , Yang P , Sun C , Chau G , Qi Y , Su X , Whitley EM , El-Naggar AK , Lozano G . 2022 . Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo . Cancer Research 82 : 1926 – 1936 . doi: 10.1158/0008-5472.CAN-21-3376 OpenUrl CrossRef PubMed ↵ Xu J , Qian J , Hu Y , Wang J , Zhou X , Chen H , Fang J-Y . 2014 . Heterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutations . Sci Rep 4 : 4223 . doi: 10.1038/srep04223 OpenUrl CrossRef PubMed ↵ Ye J , Tong Y , Lv J , Peng R , Chen S , Kuang L , Su K , Zheng Y , Zhang T , Zhang F , Jin L , Yang X , Wang H . 2020 . Rare mutations in the autophagy-regulating gene AMBRA1 contribute to human neural tube defects . Hum Mutat 41 : 1383 – 1393 . doi: 10.1002/humu.24028 OpenUrl CrossRef PubMed ↵ Zhang X , Wei H . 2021 . Role of Decidual Natural Killer Cells in Human Pregnancy and Related Pregnancy Complications . Front Immunol 12 : 728291 . doi: 10.3389/fimmu.2021.728291 OpenUrl CrossRef PubMed ↵ Zhao J , Tian Y , Zhang H , Qu L , Chen Y , Liu Q , Luo Y , Wu X . 2019 . p53 Mutant p53 N236S Induces Neural Tube Defects in Female Embryos . Int J Biol Sci 15 : 2006 – 2015 . doi: 10.7150/ijbs.31451 OpenUrl CrossRef PubMed ↵ Zhao M , Chen Y-H , Dong X-T , Zhou J , Chen X , Wang H , Wu S-X , Xia M-Z , Zhang C , Xu D-X . 2013 . Folic Acid Protects against Lipopolysaccharide-Induced Preterm Delivery and Intrauterine Growth Restriction through Its Anti-Inflammatory Effect in Mice . PLoS ONE 8 : e82713 . doi: 10.1371/journal.pone.0082713 OpenUrl CrossRef PubMed ↵ Zhao M , Wang T , Gleber-Netto FO , Chen Z , McGrail DJ , Gomez JA , Ju W , Gadhikar MA , Ma W , Shen L , Wang Q , Tang X , Pathak S , Raso MG , Burks JK , Lin S-Y , Wang J , Multani AS , Pickering CR , Chen J , Myers JN , Zhou G . 2024 . Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response . Nat Commun 15 : 180 . doi: 10.1038/s41467-023-44239-2 OpenUrl CrossRef PubMed ↵ Zhou J , Luo J , Li Peiwei , Zhou Y , Li Peichao , Wang F , Mallio CA , Rossi G , Jalal AH , Filipovic N , Tian Z , Zhao X . 2022 . Triptolide promotes degradation of the unfolded gain-of-function Tp53R175H/Y220C mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer . Transl Lung Cancer Res 11 : 802 – 816 . doi: 10.21037/tlcr-22-312 OpenUrl CrossRef PubMed View the discussion thread. Back to top Previous Next Posted February 17, 2025. Download PDF Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Oncogenic and teratogenic effects of Trp53Y217C, an inflammation-prone mouse model of the human hotspot mutant TP53Y220C Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Oncogenic and teratogenic effects of Trp53 Y217C , an inflammation-prone mouse model of the human hotspot mutant TP53 Y220C Sara Jaber , Eliana Eldawra , Jeanne Rakotopare , Iva Simeonova , Vincent Lejour , Marc Gabriel , Tatiana Cañeque , Vitalina Volochtchouk , Monika Licaj , Anne Fajac , Raphaël Rodriguez , Antonin Morillon , Boris Bardot , Franck Toledo bioRxiv 2024.09.26.615223; doi: https://doi.org/10.1101/2024.09.26.615223 Share This Article: Copy Citation Tools Oncogenic and teratogenic effects of Trp53 Y217C , an inflammation-prone mouse model of the human hotspot mutant TP53 Y220C Sara Jaber , Eliana Eldawra , Jeanne Rakotopare , Iva Simeonova , Vincent Lejour , Marc Gabriel , Tatiana Cañeque , Vitalina Volochtchouk , Monika Licaj , Anne Fajac , Raphaël Rodriguez , Antonin Morillon , Boris Bardot , Franck Toledo bioRxiv 2024.09.26.615223; doi: https://doi.org/10.1101/2024.09.26.615223 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Cancer Biology Subject Areas All Articles Animal Behavior and Cognition (7644) Biochemistry (17728) Bioengineering (13916) Bioinformatics (42037) Biophysics (21488) Cancer Biology (18636) Cell Biology (25552) Clinical Trials (138) Developmental Biology (13401) Ecology (19940) Epidemiology (2067) Evolutionary Biology (24367) Genetics (15621) Genomics (22545) Immunology (17764) Microbiology (40475) Molecular Biology (17208) Neuroscience (88744) Paleontology (667) Pathology (2842) Pharmacology and Toxicology (4834) Physiology (7659) Plant Biology (15175) Scientific Communication and Education (2047) Synthetic Biology (4304) Systems Biology (9834) Zoology (2272)